
{
    "FullStudiesResponse":{
      "APIVrs":"1.01.05",
      "DataVrs":"2023:08:16 23:57:56.293",
      "Expression":"NCT04713553",
      "NStudiesAvail":462815,
      "NStudiesFound":1,
      "MinRank":1,
      "MaxRank":1,
      "NStudiesReturned":1,
      "FullStudies":[
        {
          "Rank":1,
          "Study":{
            "ProtocolSection":{
              "IdentificationModule":{
                "NCTId":"NCT04713553",
                "OrgStudyIdInfo":{
                  "OrgStudyId":"C4591017"
                },
                "Organization":{
                  "OrgFullName":"BioNTech SE",
                  "OrgClass":"INDUSTRY"
                },
                "BriefTitle":"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants",
                "OfficialTitle":"A PHASE 3, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162b2 AGAINST COVID-19 IN HEALTHY PARTICIPANTS 12 THROUGH 50 YEARS OF AGE AND THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BNT162b2 RNA-BASED COVID-19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50 YEARS OF AGE"
              },
              "StatusModule":{
                "StatusVerifiedDate":"November 2022",
                "OverallStatus":"Completed",
                "ExpandedAccessInfo":{
                  "HasExpandedAccess":"No"
                },
                "StartDateStruct":{
                  "StartDate":"February 15, 2021",
                  "StartDateType":"Actual"
                },
                "PrimaryCompletionDateStruct":{
                  "PrimaryCompletionDate":"July 22, 2021",
                  "PrimaryCompletionDateType":"Actual"
                },
                "CompletionDateStruct":{
                  "CompletionDate":"July 22, 2021",
                  "CompletionDateType":"Actual"
                },
                "StudyFirstSubmitDate":"January 15, 2021",
                "StudyFirstSubmitQCDate":"January 15, 2021",
                "StudyFirstPostDateStruct":{
                  "StudyFirstPostDate":"January 19, 2021",
                  "StudyFirstPostDateType":"Actual"
                },
                "ResultsFirstSubmitDate":"July 18, 2022",
                "ResultsFirstSubmitQCDate":"November 30, 2022",
                "ResultsFirstPostDateStruct":{
                  "ResultsFirstPostDate":"December 22, 2022",
                  "ResultsFirstPostDateType":"Actual"
                },
                "ResultsFirstPostedQCCommentsDateStruct":{
                  "ResultsFirstPostedQCCommentsDate":"August 15, 2022",
                  "ResultsFirstPostedQCCommentsDateType":"Actual"
                },
                "LastUpdateSubmitDate":"November 30, 2022",
                "LastUpdatePostDateStruct":{
                  "LastUpdatePostDate":"December 22, 2022",
                  "LastUpdatePostDateType":"Actual"
                }
              },
              "SponsorCollaboratorsModule":{
                "ResponsibleParty":{
                  "ResponsiblePartyType":"Sponsor"
                },
                "LeadSponsor":{
                  "LeadSponsorName":"BioNTech SE",
                  "LeadSponsorClass":"INDUSTRY"
                },
                "CollaboratorList":{
                  "Collaborator":[
                    {
                      "CollaboratorName":"Pfizer",
                      "CollaboratorClass":"INDUSTRY"
                    }
                  ]
                }
              },
              "OversightModule":{
                "OversightHasDMC":"Yes",
                "IsFDARegulatedDrug":"Yes",
                "IsFDARegulatedDevice":"No"
              },
              "DescriptionModule":{
                "BriefSummary":"This is a Phase 3, randomized, observer-blind study in healthy individuals.\n\nThe primary study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate (BNT162b2):\n\nAs a 30-microgram dose, administered from 1 of 4 manufacturing lots (batches)\nAs a 20-microgram dose, administered from 1 of the manufacturing lots\nAs a 2-dose (separated by 21 days) schedule\nIn people 12 through 50 years of age\n\nThe booster study will evaluate the safety, tolerability, and immunogenicity of 2 SARS-CoV-2 RNA vaccine candidates (BNT162b2 and BNT162b2.B.1.351):\n\nEach as a 30-microgram dose\nEach as a 1-dose booster vaccine, administered approximately 3 months after Dose 2\nIn people 18 through 50 years of age"
              },
              "ConditionsModule":{
                "ConditionList":{
                  "Condition":[
                    "SARS-CoV-2 Infection",
                    "COVID-19"
                  ]
                },
                "KeywordList":{
                  "Keyword":[
                    "COVID-19",
                    "Coronavirus",
                    "Vaccine",
                    "SARS-CoV-2",
                    "RNA Vaccine",
                    "BNT162b2",
                    "BNT162B2.1.B.351"
                  ]
                }
              },
              "DesignModule":{
                "StudyType":"Interventional",
                "PhaseList":{
                  "Phase":[
                    "Phase 3"
                  ]
                },
                "DesignInfo":{
                  "DesignAllocation":"Randomized",
                  "DesignInterventionModel":"Parallel Assignment",
                  "DesignPrimaryPurpose":"Prevention",
                  "DesignMaskingInfo":{
                    "DesignMasking":"Triple",
                    "DesignWhoMaskedList":{
                      "DesignWhoMasked":[
                        "Participant",
                        "Care Provider",
                        "Investigator"
                      ]
                    }
                  }
                },
                "EnrollmentInfo":{
                  "EnrollmentCount":"1574",
                  "EnrollmentType":"Actual"
                }
              },
              "ArmsInterventionsModule":{
                "ArmGroupList":{
                  "ArmGroup":[
                    {
                      "ArmGroupLabel":"Arm 1",
                      "ArmGroupType":"Experimental",
                      "ArmGroupDescription":"30-microgram dose of US manufactured drug substance (Lot 1)",
                      "ArmGroupInterventionList":{
                        "ArmGroupInterventionName":[
                          "Biological: BNT162b2"
                        ]
                      }
                    },{
                      "ArmGroupLabel":"Arm 2",
                      "ArmGroupType":"Experimental",
                      "ArmGroupDescription":"30-microgram dose of US manufactured drug substance (Lot 2)",
                      "ArmGroupInterventionList":{
                        "ArmGroupInterventionName":[
                          "Biological: BNT162b2"
                        ]
                      }
                    },{
                      "ArmGroupLabel":"Arm 3",
                      "ArmGroupType":"Experimental",
                      "ArmGroupDescription":"30-microgram dose of US manufactured drug substance (Lot 3)",
                      "ArmGroupInterventionList":{
                        "ArmGroupInterventionName":[
                          "Biological: BNT162b2"
                        ]
                      }
                    },{
                      "ArmGroupLabel":"Arm 4",
                      "ArmGroupType":"Experimental",
                      "ArmGroupDescription":"30-microgram dose of EU manufactured drug substance (Lot 4)",
                      "ArmGroupInterventionList":{
                        "ArmGroupInterventionName":[
                          "Biological: BNT162b2"
                        ]
                      }
                    },{
                      "ArmGroupLabel":"Arm 5",
                      "ArmGroupType":"Experimental",
                      "ArmGroupDescription":"20-microgram dose of US manufactured drug substance (corresponding to Arm 1, 2 or 3 lot)",
                      "ArmGroupInterventionList":{
                        "ArmGroupInterventionName":[
                          "Biological: BNT162b2"
                        ]
                      }
                    },{
                      "ArmGroupLabel":"Booster 1: BNT162b2",
                      "ArmGroupType":"Experimental",
                      "ArmGroupDescription":"30-microgram dose",
                      "ArmGroupInterventionList":{
                        "ArmGroupInterventionName":[
                          "Biological: BNT162b2"
                        ]
                      }
                    },{
                      "ArmGroupLabel":"Booster 2: BNT162b2.B.1.351",
                      "ArmGroupType":"Experimental",
                      "ArmGroupDescription":"30-microgram dose",
                      "ArmGroupInterventionList":{
                        "ArmGroupInterventionName":[
                          "Biological: BNT162b2.B.1.351"
                        ]
                      }
                    }
                  ]
                },
                "InterventionList":{
                  "Intervention":[
                    {
                      "InterventionType":"Biological",
                      "InterventionName":"BNT162b2",
                      "InterventionDescription":"Intramuscular injection",
                      "InterventionArmGroupLabelList":{
                        "InterventionArmGroupLabel":[
                          "Arm 1",
                          "Arm 2",
                          "Arm 3",
                          "Arm 4",
                          "Arm 5",
                          "Booster 1: BNT162b2"
                        ]
                      }
                    },{
                      "InterventionType":"Biological",
                      "InterventionName":"BNT162b2.B.1.351",
                      "InterventionDescription":"Intramuscular injection",
                      "InterventionArmGroupLabelList":{
                        "InterventionArmGroupLabel":[
                          "Booster 2: BNT162b2.B.1.351"
                        ]
                      }
                    }
                  ]
                }
              },
              "OutcomesModule":{
                "PrimaryOutcomeList":{
                  "PrimaryOutcome":[
                    {
                      "PrimaryOutcomeMeasure":"Geometric Mean Ratios (GMRs) of Full-Length S-Binding Immunoglobulin G (IgG) Concentrations Between Individual US Lots 1, 2, and 3 at 1 Month After Dose 2: Primary Study",
                      "PrimaryOutcomeDescription":"Geometric mean concentration of full-length S-binding IgG level for individual US lots (US lots 1, 2, and 3) was determined and reported in the descriptive section. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratio of Geometric Mean Concentrations (GMCs) of individual US Lots BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3.",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 2"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Ratios (GMRs) of Full-Length S-Binding IgG Concentrations Between EU Lot and Pooled US Lots at 1 Month After Dose 2: Primary Study",
                      "PrimaryOutcomeDescription":"Geometric mean concentration of full-length S-binding IgG level for EU lot and pooled US lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm) were determined and reported in the descriptive section. Assay results below the LLOQ were set to 0.5*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratios of GMCs of BNT162b2 30 mcg: EU Lot and pooled US Lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm).",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 2"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Ratios (GMRs) of SARS-CoV-2 Neutralizing Titers Between 20-microgram Dose and 30-microgram Dose at 1 Month After Dose 2: Primary Study",
                      "PrimaryOutcomeDescription":"Geometric mean titer for SARS-CoV-2 neutralizing titers for 20 mcg dose and 30 mcg dose of US Lot 1 was determined and reported in the descriptive section. GMTs and 2-sided 95% CIs were calculated by exponentiating the least square (LS) mean of the titers and corresponding CIs based on linear regression model. Assay results below the LLOQ were set to 0.5*LLOQ. GMRs were reported in the statistical analysis section and were calculated as the ratio of geometric mean titer of the 20-mcg dose (US Lot 1) to the geometric mean titer of the 30 mcg dose (US Lot 1).",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 2"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study",
                      "PrimaryOutcomeDescription":"Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 1. Redness, swelling, and pain at injection site after Dose 1 were reported.",
                      "PrimaryOutcomeTimeFrame":"Within 7 days after Dose 1"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Primary Study",
                      "PrimaryOutcomeDescription":"Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 2. Redness, swelling, and pain at injection site after Dose 2 were reported.",
                      "PrimaryOutcomeTimeFrame":"Within 7 days after Dose 2"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Local Reactions Within 7 Days After Any Dose: Primary Study",
                      "PrimaryOutcomeDescription":"Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination. Redness, swelling, and pain at injection site after any dose were reported.",
                      "PrimaryOutcomeTimeFrame":"Within 7 days after any dose"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 3. Redness, swelling, and pain at injection site after Dose 3 were reported.",
                      "PrimaryOutcomeTimeFrame":"Within 7 days after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Primary Study",
                      "PrimaryOutcomeDescription":"Systemic events were reported using an electronic diary. Fever was defined as temperature >=38.0 degree Celsius (C) and categorized as >=38.0 to 38.4 C; >38.4 to 38.9 C; >38.9 to 40.0 C; >40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 1 were reported.",
                      "PrimaryOutcomeTimeFrame":"Within 7 days after Dose 1"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Primary Study",
                      "PrimaryOutcomeDescription":"Systemic events were reported using an electronic diary. Fever was defined as temperature >=38.0 C and categorized as >=38.0 to 38.4 C; >38.4 to 38.9 C; >38.9 to 40.0 C; >40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 2 were reported.",
                      "PrimaryOutcomeTimeFrame":"Within 7 days after Dose 2"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Systemic Events Within 7 Days After Any Dose: Primary Study",
                      "PrimaryOutcomeDescription":"Systemic events were reported using an electronic diary. Fever was defined as temperature >=38.0 C and categorized as >=38.0 to 38.4 C; >38.4 to 38.9 C; >38.9 to 40.0 C; >40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after any dose were reported.",
                      "PrimaryOutcomeTimeFrame":"Within 7 days after any dose"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"Systemic events were reported using an electronic diary. Fever was defined as temperature >=38.0 C and categorized as >=38.0 to 38.4 C; >38.4 to 38.9 C; >38.9 to 40.0 C; >40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 3 were reported.",
                      "PrimaryOutcomeTimeFrame":"Within 7 days after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 2: Primary Study",
                      "PrimaryOutcomeDescription":"An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.",
                      "PrimaryOutcomeTimeFrame":"Day 1 of Dose 1 up to 1 Month after Dose 2 (for a maximum of 2 months)"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 3 to 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.",
                      "PrimaryOutcomeTimeFrame":"From Dose 3 to 1 Month after Dose 3 (for a maximum of 35 days)"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain at Baseline: Booster Study",
                      "PrimaryOutcomeDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "PrimaryOutcomeTimeFrame":"Baseline (prior to Dose 1 of Primary study)"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 2: Booster Study",
                      "PrimaryOutcomeDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 2 of primary study"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain Before Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "PrimaryOutcomeTimeFrame":"Before Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Week After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "PrimaryOutcomeTimeFrame":"1 Week after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain at Baseline: Booster Study",
                      "PrimaryOutcomeDescription":"GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).",
                      "PrimaryOutcomeTimeFrame":"Baseline (prior to Dose 1 of Primary study)"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 2: Booster Study",
                      "PrimaryOutcomeDescription":"GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 2 of primary study"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain Before Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "PrimaryOutcomeTimeFrame":"Before Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Week After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "PrimaryOutcomeTimeFrame":"1 Week after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Booster Study",
                      "PrimaryOutcomeDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"Baseline (prior to Dose 1 of Primary study)"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 2: Booster Study",
                      "PrimaryOutcomeDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 2 of primary study"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels Before Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"Before Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Week After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"1 Week after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"From 1 Month after Dose 2 to 1 Week after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"From 1 Month after Dose 2 to 1 Month after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Week After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"Before Dose 3 to 1 Week after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"Before Dose 3 to 1 Month after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"From 1 Month after Dose 2 to 1 Week after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"From 1 Month after Dose 2 to 1 Month after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Week After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"Before Dose 3 to 1 Week after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"Before Dose 3 to 1 Month after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).",
                      "PrimaryOutcomeTimeFrame":"From 1 Month after Dose 2 to 1 Week after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).",
                      "PrimaryOutcomeTimeFrame":"From 1 Month after Dose 2 to 1 Month after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Week After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"Before Dose 3 to 1 Week after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "PrimaryOutcomeTimeFrame":"Before Dose 3 to 1 Month after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Seroresponse to Reference Strain at 1 Month After Dose 2: Booster Study",
                      "PrimaryOutcomeDescription":"Seroresponse was defined as greater than equal to (>=) 4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of >=4*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 2"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Seroresponse to Reference Strain Before Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of >=4*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.",
                      "PrimaryOutcomeTimeFrame":"Before Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Seroresponse to Reference Strain 1 Week After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of >=4*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.",
                      "PrimaryOutcomeTimeFrame":"1 Week after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Seroresponse to Reference Strain 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of >=4*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Seroresponse to B.1.351 Variant Strain at 1 Month After Dose 2: Booster Study",
                      "PrimaryOutcomeDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 2"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Seroresponse to B.1.351 Variant Strain Before Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.",
                      "PrimaryOutcomeTimeFrame":"Before Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Seroresponse to B.1.351 Variant Strain 1 Week After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.",
                      "PrimaryOutcomeTimeFrame":"1 Week after Dose 3"
                    },{
                      "PrimaryOutcomeMeasure":"Percentage of Participants With Seroresponse to B.1.351 Variant Strain 1 Month After Dose 3: Booster Study",
                      "PrimaryOutcomeDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.",
                      "PrimaryOutcomeTimeFrame":"1 Month after Dose 3"
                    }
                  ]
                },
                "SecondaryOutcomeList":{
                  "SecondaryOutcome":[
                    {
                      "SecondaryOutcomeMeasure":"Geometric Mean Concentrations (GMCs) of Full-Length S-Binding IgG Levels at Baseline and 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study",
                      "SecondaryOutcomeDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5* LLOQ.",
                      "SecondaryOutcomeTimeFrame":"Baseline (before Dose 1), 1 Month after Dose 2"
                    },{
                      "SecondaryOutcomeMeasure":"Geometric Mean Fold Rises (GMFRs) in Full-Length S-Binding lgG Levels From Baseline to 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study",
                      "SecondaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "SecondaryOutcomeTimeFrame":"From Baseline (before Dose 1) up to 1 Month after Dose 2"
                    },{
                      "SecondaryOutcomeMeasure":"Geometric Mean Titers (GMT) of SARS-CoV-2 Neutralizing Titers at Baseline and 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study",
                      "SecondaryOutcomeDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5* LLOQ.",
                      "SecondaryOutcomeTimeFrame":"Baseline (before Dose 1), 1 Month after Dose 2"
                    },{
                      "SecondaryOutcomeMeasure":"Geometric Mean Fold Rises (GMFRs) in SARS-CoV-2 Neutralizing Titers From Baseline to 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study",
                      "SecondaryOutcomeDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 at 1 month after Dose 2 to the geometric mean titers of SARS-CoV-2 at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5* LLOQ.",
                      "SecondaryOutcomeTimeFrame":"From Baseline (before Dose 1) up to 1 Month after Dose 2"
                    }
                  ]
                }
              },
              "EligibilityModule":{
                "EligibilityCriteria":"Inclusion Criteria:\n\nPrimary study: Male or female participants between the ages of 12 and 50 years, inclusive, at randomization.\nBooster study: Male or female participants between the ages of 18 and 50 years, inclusive, at rerandomization.\nParticipants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.\nHealthy participants who are determined by medical history, physical examination (if required), and clinical judgment of the investigator to be eligible for inclusion in the study.\nCapable of giving personal signed informed consent/have parent(s)/legal guardian capable of giving signed informed consent.\n\nExclusion Criteria:\n\nOther medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.\nKnown infection with HIV, HCV, or HBV.\nHistory of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention.\n\nPrevious clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19.\n\n. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.\n\nBleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.\nWomen who are pregnant or breastfeeding.\nPrimary study: Previous vaccination with any coronavirus vaccine.\nBooster study: Previous vaccination with any coronavirus vaccine outside of this study.\nReceipt of medications intended to prevent COVID-19.\nIndividuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study.\nReceipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.\nParticipation in other studies involving study intervention within 28 days prior to study entry and/or during study participation.\nPrevious participation in other studies involving study intervention containing lipid nanoparticles.\nInvestigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.\n\nAdditional Exclusion Criteria for the Booster study:\n\nCurrent febrile illness (body temperature ≥100.4°F [≥38.0°C]) or other acute illness within 48 hours before study intervention administration.\nReceipt of any seasonal or pandemic influenza vaccine within 14 days, or any other nonstudy vaccine within 28 days, before or after study intervention administration.\nReceipt of short-term (<14 days) systemic corticosteroids. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.",
                "HealthyVolunteers":"Accepts Healthy Volunteers",
                "Gender":"All",
                "MinimumAge":"12 Years",
                "MaximumAge":"50 Years",
                "StdAgeList":{
                  "StdAge":[
                    "Child",
                    "Adult"
                  ]
                }
              },
              "ContactsLocationsModule":{
                "OverallOfficialList":{
                  "OverallOfficial":[
                    {
                      "OverallOfficialName":"Pfizer CT.gov Call Center",
                      "OverallOfficialAffiliation":"Pfizer",
                      "OverallOfficialRole":"Study Director"
                    }
                  ]
                },
                "LocationList":{
                  "Location":[
                    {
                      "LocationFacility":"Kaiser Permanente Oakland",
                      "LocationCity":"Oakland",
                      "LocationState":"California",
                      "LocationZip":"94611",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Clinical Research Consulting",
                      "LocationCity":"Milford",
                      "LocationState":"Connecticut",
                      "LocationZip":"06460",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Indago Research & Health Center, Inc",
                      "LocationCity":"Hialeah",
                      "LocationState":"Florida",
                      "LocationZip":"33012",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Research Centers of America",
                      "LocationCity":"Hollywood",
                      "LocationState":"Florida",
                      "LocationZip":"33024",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Clinical Neuroscience Solutions",
                      "LocationCity":"Orlando",
                      "LocationState":"Florida",
                      "LocationZip":"32801",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Clinical Research Atlanta",
                      "LocationCity":"Stockbridge",
                      "LocationState":"Georgia",
                      "LocationZip":"30281",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"East-West Medical Research Institute",
                      "LocationCity":"Honolulu",
                      "LocationState":"Hawaii",
                      "LocationZip":"96814",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Solaris Clinical Research",
                      "LocationCity":"Meridian",
                      "LocationState":"Idaho",
                      "LocationZip":"83646",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Kentucky Pediatric/Adult Research",
                      "LocationCity":"Bardstown",
                      "LocationState":"Kentucky",
                      "LocationZip":"40004",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Amici Clinical Research LLC",
                      "LocationCity":"Raritan",
                      "LocationState":"New Jersey",
                      "LocationZip":"08869",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Accellacare - Wilmington",
                      "LocationCity":"Wilmington",
                      "LocationState":"North Carolina",
                      "LocationZip":"28401",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Cincinnati Children's Hospital Medical Center",
                      "LocationCity":"Cincinnati",
                      "LocationState":"Ohio",
                      "LocationZip":"45206",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Cincinnati Children's Hospital Medical Center",
                      "LocationCity":"Cincinnati",
                      "LocationState":"Ohio",
                      "LocationZip":"45229-3039",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Texas Center for Drug Development, Inc.",
                      "LocationCity":"Houston",
                      "LocationState":"Texas",
                      "LocationZip":"77081",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Clinical Trials of Texas, LLC",
                      "LocationCity":"San Antonio",
                      "LocationState":"Texas",
                      "LocationZip":"78229",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"Martin Diagnostic Clinic",
                      "LocationCity":"Tomball",
                      "LocationState":"Texas",
                      "LocationZip":"77375",
                      "LocationCountry":"United States"
                    },{
                      "LocationFacility":"J. Lewis Research, Inc. / Foothill Family Clinic South",
                      "LocationCity":"Salt Lake City",
                      "LocationState":"Utah",
                      "LocationZip":"84121",
                      "LocationCountry":"United States"
                    }
                  ]
                }
              },
              "ReferencesModule":{
                "SeeAlsoLinkList":{
                  "SeeAlsoLink":[
                    {
                      "SeeAlsoLinkLabel":"To obtain contact information for a study center near you, click here.",
                      "SeeAlsoLinkURL":"https://pmiform.com/clinical-trial-info-request?StudyID=C4591017"
                    }
                  ]
                }
              },
              "IPDSharingStatementModule":{
                "IPDSharing":"No"
              }
            },
            "ResultsSection":{
              "ParticipantFlowModule":{
                "FlowPreAssignmentDetails":"Total number of participants enrolled in study and assigned to study intervention were 1574, however, only 1573 participants received study intervention.",
                "FlowRecruitmentDetails":"This study was conducted in two parts: primary study and booster study.",
                "FlowGroupList":{
                  "FlowGroup":[
                    {
                      "FlowGroupId":"FG000",
                      "FlowGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                      "FlowGroupDescription":"Participants were randomized in primary study to receive 30 microgram (mcg) intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                    },{
                      "FlowGroupId":"FG001",
                      "FlowGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                      "FlowGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                    },{
                      "FlowGroupId":"FG002",
                      "FlowGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                      "FlowGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                    },{
                      "FlowGroupId":"FG003",
                      "FlowGroupTitle":"BNT162b2 30 mcg: EU Lot",
                      "FlowGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                    },{
                      "FlowGroupId":"FG004",
                      "FlowGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                      "FlowGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                    },{
                      "FlowGroupId":"FG005",
                      "FlowGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                      "FlowGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                    },{
                      "FlowGroupId":"FG006",
                      "FlowGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                      "FlowGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                    }
                  ]
                },
                "FlowPeriodList":{
                  "FlowPeriod":[
                    {
                      "FlowPeriodTitle":"Primary Study (2 Months)",
                      "FlowMilestoneList":{
                        "FlowMilestone":[
                          {
                            "FlowMilestoneType":"STARTED",
                            "FlowAchievementList":{
                              "FlowAchievement":[
                                {
                                  "FlowAchievementGroupId":"FG000",
                                  "FlowAchievementNumSubjects":"351"
                                },{
                                  "FlowAchievementGroupId":"FG001",
                                  "FlowAchievementNumSubjects":"352"
                                },{
                                  "FlowAchievementGroupId":"FG002",
                                  "FlowAchievementNumSubjects":"347"
                                },{
                                  "FlowAchievementGroupId":"FG003",
                                  "FlowAchievementNumSubjects":"173"
                                },{
                                  "FlowAchievementGroupId":"FG004",
                                  "FlowAchievementNumSubjects":"351"
                                },{
                                  "FlowAchievementGroupId":"FG005",
                                  "FlowAchievementComment":"No participants were enrolled in this arm during the primary study.",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG006",
                                  "FlowAchievementComment":"No participants were enrolled in this arm during the primary study.",
                                  "FlowAchievementNumSubjects":"0"
                                }
                              ]
                            }
                          },{
                            "FlowMilestoneType":"Treated",
                            "FlowAchievementList":{
                              "FlowAchievement":[
                                {
                                  "FlowAchievementGroupId":"FG000",
                                  "FlowAchievementNumSubjects":"351"
                                },{
                                  "FlowAchievementGroupId":"FG001",
                                  "FlowAchievementNumSubjects":"352"
                                },{
                                  "FlowAchievementGroupId":"FG002",
                                  "FlowAchievementNumSubjects":"346"
                                },{
                                  "FlowAchievementGroupId":"FG003",
                                  "FlowAchievementNumSubjects":"173"
                                },{
                                  "FlowAchievementGroupId":"FG004",
                                  "FlowAchievementNumSubjects":"351"
                                },{
                                  "FlowAchievementGroupId":"FG005",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG006",
                                  "FlowAchievementNumSubjects":"0"
                                }
                              ]
                            }
                          },{
                            "FlowMilestoneType":"COMPLETED",
                            "FlowAchievementList":{
                              "FlowAchievement":[
                                {
                                  "FlowAchievementGroupId":"FG000",
                                  "FlowAchievementNumSubjects":"347"
                                },{
                                  "FlowAchievementGroupId":"FG001",
                                  "FlowAchievementNumSubjects":"346"
                                },{
                                  "FlowAchievementGroupId":"FG002",
                                  "FlowAchievementNumSubjects":"344"
                                },{
                                  "FlowAchievementGroupId":"FG003",
                                  "FlowAchievementNumSubjects":"171"
                                },{
                                  "FlowAchievementGroupId":"FG004",
                                  "FlowAchievementNumSubjects":"349"
                                },{
                                  "FlowAchievementGroupId":"FG005",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG006",
                                  "FlowAchievementNumSubjects":"0"
                                }
                              ]
                            }
                          },{
                            "FlowMilestoneType":"NOT COMPLETED",
                            "FlowAchievementList":{
                              "FlowAchievement":[
                                {
                                  "FlowAchievementGroupId":"FG000",
                                  "FlowAchievementNumSubjects":"4"
                                },{
                                  "FlowAchievementGroupId":"FG001",
                                  "FlowAchievementNumSubjects":"6"
                                },{
                                  "FlowAchievementGroupId":"FG002",
                                  "FlowAchievementNumSubjects":"3"
                                },{
                                  "FlowAchievementGroupId":"FG003",
                                  "FlowAchievementNumSubjects":"2"
                                },{
                                  "FlowAchievementGroupId":"FG004",
                                  "FlowAchievementNumSubjects":"2"
                                },{
                                  "FlowAchievementGroupId":"FG005",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG006",
                                  "FlowAchievementNumSubjects":"0"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "FlowDropWithdrawList":{
                        "FlowDropWithdraw":[
                          {
                            "FlowDropWithdrawType":"Withdrawal by Subject",
                            "FlowReasonList":{
                              "FlowReason":[
                                {
                                  "FlowReasonGroupId":"FG000",
                                  "FlowReasonNumSubjects":"2"
                                },{
                                  "FlowReasonGroupId":"FG001",
                                  "FlowReasonNumSubjects":"3"
                                },{
                                  "FlowReasonGroupId":"FG002",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG003",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG004",
                                  "FlowReasonNumSubjects":"1"
                                },{
                                  "FlowReasonGroupId":"FG005",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG006",
                                  "FlowReasonNumSubjects":"0"
                                }
                              ]
                            }
                          },{
                            "FlowDropWithdrawType":"Withdrawal by parent/guardian",
                            "FlowReasonList":{
                              "FlowReason":[
                                {
                                  "FlowReasonGroupId":"FG000",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG001",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG002",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG003",
                                  "FlowReasonNumSubjects":"1"
                                },{
                                  "FlowReasonGroupId":"FG004",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG005",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG006",
                                  "FlowReasonNumSubjects":"0"
                                }
                              ]
                            }
                          },{
                            "FlowDropWithdrawType":"Other",
                            "FlowReasonList":{
                              "FlowReason":[
                                {
                                  "FlowReasonGroupId":"FG000",
                                  "FlowReasonNumSubjects":"1"
                                },{
                                  "FlowReasonGroupId":"FG001",
                                  "FlowReasonNumSubjects":"2"
                                },{
                                  "FlowReasonGroupId":"FG002",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG003",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG004",
                                  "FlowReasonNumSubjects":"1"
                                },{
                                  "FlowReasonGroupId":"FG005",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG006",
                                  "FlowReasonNumSubjects":"0"
                                }
                              ]
                            }
                          },{
                            "FlowDropWithdrawType":"Lost to Follow-up",
                            "FlowReasonList":{
                              "FlowReason":[
                                {
                                  "FlowReasonGroupId":"FG000",
                                  "FlowReasonNumSubjects":"1"
                                },{
                                  "FlowReasonGroupId":"FG001",
                                  "FlowReasonNumSubjects":"1"
                                },{
                                  "FlowReasonGroupId":"FG002",
                                  "FlowReasonNumSubjects":"2"
                                },{
                                  "FlowReasonGroupId":"FG003",
                                  "FlowReasonNumSubjects":"1"
                                },{
                                  "FlowReasonGroupId":"FG004",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG005",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG006",
                                  "FlowReasonNumSubjects":"0"
                                }
                              ]
                            }
                          },{
                            "FlowDropWithdrawType":"Inclusion criteria not met",
                            "FlowReasonList":{
                              "FlowReason":[
                                {
                                  "FlowReasonGroupId":"FG000",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG001",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG002",
                                  "FlowReasonNumSubjects":"1"
                                },{
                                  "FlowReasonGroupId":"FG003",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG004",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG005",
                                  "FlowReasonNumSubjects":"0"
                                },{
                                  "FlowReasonGroupId":"FG006",
                                  "FlowReasonNumSubjects":"0"
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "FlowPeriodTitle":"Booster Study (1 Month)",
                      "FlowMilestoneList":{
                        "FlowMilestone":[
                          {
                            "FlowMilestoneType":"STARTED",
                            "FlowAchievementList":{
                              "FlowAchievement":[
                                {
                                  "FlowAchievementGroupId":"FG000",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG001",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG002",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG003",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG004",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG005",
                                  "FlowAchievementNumSubjects":"31"
                                },{
                                  "FlowAchievementGroupId":"FG006",
                                  "FlowAchievementNumSubjects":"31"
                                }
                              ]
                            }
                          },{
                            "FlowMilestoneType":"COMPLETED",
                            "FlowAchievementList":{
                              "FlowAchievement":[
                                {
                                  "FlowAchievementGroupId":"FG000",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG001",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG002",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG003",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG004",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG005",
                                  "FlowAchievementNumSubjects":"31"
                                },{
                                  "FlowAchievementGroupId":"FG006",
                                  "FlowAchievementNumSubjects":"31"
                                }
                              ]
                            }
                          },{
                            "FlowMilestoneType":"NOT COMPLETED",
                            "FlowAchievementList":{
                              "FlowAchievement":[
                                {
                                  "FlowAchievementGroupId":"FG000",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG001",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG002",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG003",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG004",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG005",
                                  "FlowAchievementNumSubjects":"0"
                                },{
                                  "FlowAchievementGroupId":"FG006",
                                  "FlowAchievementNumSubjects":"0"
                                }
                              ]
                            }
                          }
                        ]
                      }
                    }
                  ]
                }
              },
              "BaselineCharacteristicsModule":{
                "BaselinePopulationDescription":"Safety Population comprising of all randomized participants who received at least 1 dose of the study intervention were included.",
                "BaselineGroupList":{
                  "BaselineGroup":[
                    {
                      "BaselineGroupId":"BG000",
                      "BaselineGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                      "BaselineGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                    },{
                      "BaselineGroupId":"BG001",
                      "BaselineGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                      "BaselineGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                    },{
                      "BaselineGroupId":"BG002",
                      "BaselineGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                      "BaselineGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                    },{
                      "BaselineGroupId":"BG003",
                      "BaselineGroupTitle":"BNT162b2 30 mcg: EU Lot",
                      "BaselineGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                    },{
                      "BaselineGroupId":"BG004",
                      "BaselineGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                      "BaselineGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                    },{
                      "BaselineGroupId":"BG005",
                      "BaselineGroupTitle":"Total",
                      "BaselineGroupDescription":"Total of all reporting groups"
                    }
                  ]
                },
                "BaselineDenomList":{
                  "BaselineDenom":[
                    {
                      "BaselineDenomUnits":"Participants",
                      "BaselineDenomCountList":{
                        "BaselineDenomCount":[
                          {
                            "BaselineDenomCountGroupId":"BG000",
                            "BaselineDenomCountValue":"351"
                          },{
                            "BaselineDenomCountGroupId":"BG001",
                            "BaselineDenomCountValue":"352"
                          },{
                            "BaselineDenomCountGroupId":"BG002",
                            "BaselineDenomCountValue":"346"
                          },{
                            "BaselineDenomCountGroupId":"BG003",
                            "BaselineDenomCountValue":"173"
                          },{
                            "BaselineDenomCountGroupId":"BG004",
                            "BaselineDenomCountValue":"351"
                          },{
                            "BaselineDenomCountGroupId":"BG005",
                            "BaselineDenomCountValue":"1573"
                          }
                        ]
                      }
                    }
                  ]
                },
                "BaselineMeasureList":{
                  "BaselineMeasure":[
                    {
                      "BaselineMeasureTitle":"Age, Continuous",
                      "BaselineMeasureParamType":"Mean",
                      "BaselineMeasureDispersionType":"Standard Deviation",
                      "BaselineMeasureUnitOfMeasure":"Years",
                      "BaselineClassList":{
                        "BaselineClass":[
                          {
                            "BaselineCategoryList":{
                              "BaselineCategory":[
                                {
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"28.0",
                                        "BaselineMeasurementSpread":"11.66"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"27.8",
                                        "BaselineMeasurementSpread":"11.76"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"27.5",
                                        "BaselineMeasurementSpread":"11.54"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"27.7",
                                        "BaselineMeasurementSpread":"11.40"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"27.5",
                                        "BaselineMeasurementSpread":"11.71"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"27.7",
                                        "BaselineMeasurementSpread":"11.63"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "BaselineMeasureTitle":"Sex: Female, Male",
                      "BaselineMeasureParamType":"Count of Participants",
                      "BaselineMeasureUnitOfMeasure":"Participants",
                      "BaselineClassList":{
                        "BaselineClass":[
                          {
                            "BaselineCategoryList":{
                              "BaselineCategory":[
                                {
                                  "BaselineCategoryTitle":"Female",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"177"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"176"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"159"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"83"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"163"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"758"
                                      }
                                    ]
                                  }
                                },{
                                  "BaselineCategoryTitle":"Male",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"174"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"176"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"187"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"90"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"188"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"815"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "BaselineMeasureTitle":"Ethnicity (NIH/OMB)",
                      "BaselineMeasureParamType":"Count of Participants",
                      "BaselineMeasureUnitOfMeasure":"Participants",
                      "BaselineClassList":{
                        "BaselineClass":[
                          {
                            "BaselineCategoryList":{
                              "BaselineCategory":[
                                {
                                  "BaselineCategoryTitle":"Hispanic or Latino",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"44"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"32"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"55"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"22"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"42"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"195"
                                      }
                                    ]
                                  }
                                },{
                                  "BaselineCategoryTitle":"Not Hispanic or Latino",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"306"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"319"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"291"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"151"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"309"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"1376"
                                      }
                                    ]
                                  }
                                },{
                                  "BaselineCategoryTitle":"Unknown or Not Reported",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"1"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"1"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"0"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"0"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"0"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"2"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "BaselineMeasureTitle":"Race (NIH/OMB)",
                      "BaselineMeasureParamType":"Count of Participants",
                      "BaselineMeasureUnitOfMeasure":"Participants",
                      "BaselineClassList":{
                        "BaselineClass":[
                          {
                            "BaselineCategoryList":{
                              "BaselineCategory":[
                                {
                                  "BaselineCategoryTitle":"American Indian or Alaska Native",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"0"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"1"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"1"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"0"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"3"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"5"
                                      }
                                    ]
                                  }
                                },{
                                  "BaselineCategoryTitle":"Asian",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"36"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"48"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"40"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"24"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"44"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"192"
                                      }
                                    ]
                                  }
                                },{
                                  "BaselineCategoryTitle":"Native Hawaiian or Other Pacific Islander",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"1"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"1"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"1"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"0"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"2"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"5"
                                      }
                                    ]
                                  }
                                },{
                                  "BaselineCategoryTitle":"Black or African American",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"21"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"16"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"15"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"2"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"14"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"68"
                                      }
                                    ]
                                  }
                                },{
                                  "BaselineCategoryTitle":"White",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"286"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"280"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"283"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"142"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"283"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"1274"
                                      }
                                    ]
                                  }
                                },{
                                  "BaselineCategoryTitle":"More than one race",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"6"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"5"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"5"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"4"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"5"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"25"
                                      }
                                    ]
                                  }
                                },{
                                  "BaselineCategoryTitle":"Unknown or Not Reported",
                                  "BaselineMeasurementList":{
                                    "BaselineMeasurement":[
                                      {
                                        "BaselineMeasurementGroupId":"BG000",
                                        "BaselineMeasurementValue":"1"
                                      },{
                                        "BaselineMeasurementGroupId":"BG001",
                                        "BaselineMeasurementValue":"1"
                                      },{
                                        "BaselineMeasurementGroupId":"BG002",
                                        "BaselineMeasurementValue":"1"
                                      },{
                                        "BaselineMeasurementGroupId":"BG003",
                                        "BaselineMeasurementValue":"1"
                                      },{
                                        "BaselineMeasurementGroupId":"BG004",
                                        "BaselineMeasurementValue":"0"
                                      },{
                                        "BaselineMeasurementGroupId":"BG005",
                                        "BaselineMeasurementValue":"4"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    }
                  ]
                }
              },
              "OutcomeMeasuresModule":{
                "OutcomeMeasureList":{
                  "OutcomeMeasure":[
                    {
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Ratios (GMRs) of Full-Length S-Binding Immunoglobulin G (IgG) Concentrations Between Individual US Lots 1, 2, and 3 at 1 Month After Dose 2: Primary Study",
                      "OutcomeMeasureDescription":"Geometric mean concentration of full-length S-binding IgG level for individual US lots (US lots 1, 2, and 3) was determined and reported in the descriptive section. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratio of Geometric Mean Concentrations (GMCs) of individual US Lots BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3.",
                      "OutcomeMeasurePopulationDescription":"Evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, with Dose 2 received within predefined window, had at least 1 valid immunogenicity result from blood sample collected within an appropriate window at 1 month after Dose 2, were negative for both SARS-CoV-2 test (RT-PCR and N-blinding antibody) during study and had no other protocol deviations determined by clinician. Here, \"N\"= participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Unit per milliliter",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 2",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG002",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"324"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"311"
                                },{
                                  "OutcomeDenomCountGroupId":"OG002",
                                  "OutcomeDenomCountValue":"310"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"6299.5",
                                        "OutcomeMeasurementSpread":"5835.4",
                                        "OutcomeMeasurementLowerLimit":"5835.4",
                                        "OutcomeMeasurementUpperLimit":"6800.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6231.9",
                                        "OutcomeMeasurementSpread":"5763.7",
                                        "OutcomeMeasurementLowerLimit":"5763.7",
                                        "OutcomeMeasurementUpperLimit":"6738.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"6774.8",
                                        "OutcomeMeasurementSpread":"6264.9",
                                        "OutcomeMeasurementLowerLimit":"6264.9",
                                        "OutcomeMeasurementUpperLimit":"7326.1"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeAnalysisList":{
                        "OutcomeAnalysis":[
                          {
                            "OutcomeAnalysisGroupIdList":{
                              "OutcomeAnalysisGroupId":[
                                "OG000",
                                "OG001"
                              ]
                            },
                            "OutcomeAnalysisNonInferiorityType":"Equivalence",
                            "OutcomeAnalysisNonInferiorityComment":"Equivalence was to be achieved if the 2-sided 95% confidence interval (CI) for GMR falls within the interval (0.67, 1.5).",
                            "OutcomeAnalysisParamType":"Geometric mean ratio",
                            "OutcomeAnalysisParamValue":"1.01",
                            "OutcomeAnalysisCIPctValue":"95",
                            "OutcomeAnalysisCINumSides":"2-Sided",
                            "OutcomeAnalysisCILowerLimit":"0.91",
                            "OutcomeAnalysisCIUpperLimit":"1.13",
                            "OutcomeAnalysisEstimateComment":"GMRs and corresponding 2-sided 95% CIs were calculated by exponentiating difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of age and vaccine group."
                          },{
                            "OutcomeAnalysisGroupIdList":{
                              "OutcomeAnalysisGroupId":[
                                "OG000",
                                "OG002"
                              ]
                            },
                            "OutcomeAnalysisNonInferiorityType":"Equivalence",
                            "OutcomeAnalysisNonInferiorityComment":"Equivalence was to be achieved if the 2-sided 95% CI for GMR falls within the interval (0.67, 1.5).",
                            "OutcomeAnalysisParamType":"Geometric mean ratio",
                            "OutcomeAnalysisParamValue":"0.93",
                            "OutcomeAnalysisCIPctValue":"95",
                            "OutcomeAnalysisCINumSides":"2-Sided",
                            "OutcomeAnalysisCILowerLimit":"0.83",
                            "OutcomeAnalysisCIUpperLimit":"1.04",
                            "OutcomeAnalysisEstimateComment":"GMRs and corresponding 2-sided 95% CIs were calculated by exponentiating difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of age and vaccine group."
                          },{
                            "OutcomeAnalysisGroupIdList":{
                              "OutcomeAnalysisGroupId":[
                                "OG001",
                                "OG002"
                              ]
                            },
                            "OutcomeAnalysisNonInferiorityType":"Equivalence",
                            "OutcomeAnalysisNonInferiorityComment":"Equivalence was to be achieved if the 2-sided 95% CI for GMR falls within the interval (0.67, 1.5).",
                            "OutcomeAnalysisParamType":"Geometric mean ratio",
                            "OutcomeAnalysisParamValue":"0.92",
                            "OutcomeAnalysisCIPctValue":"95",
                            "OutcomeAnalysisCINumSides":"2-Sided",
                            "OutcomeAnalysisCILowerLimit":"0.82",
                            "OutcomeAnalysisCIUpperLimit":"1.03",
                            "OutcomeAnalysisEstimateComment":"GMRs and corresponding 2-sided 95% CIs were calculated by exponentiating difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of age and vaccine group."
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Ratios (GMRs) of Full-Length S-Binding IgG Concentrations Between EU Lot and Pooled US Lots at 1 Month After Dose 2: Primary Study",
                      "OutcomeMeasureDescription":"Geometric mean concentration of full-length S-binding IgG level for EU lot and pooled US lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm) were determined and reported in the descriptive section. Assay results below the LLOQ were set to 0.5*LLOQ. GMRs were reported in the statistical analysis section and was calculated as ratios of GMCs of BNT162b2 30 mcg: EU Lot and pooled US Lots (BNT162b2 30 mcg: US Lot 1, BNT162b2 30 mcg: US Lot 2 and BNT162b2 30 mcg: US Lot 3 reporting arm).",
                      "OutcomeMeasurePopulationDescription":"Evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, with Dose 2 received within predefined window, had at least 1 valid immunogenicity result from blood sample collected within an appropriate window at 1 month after Dose 2, were negative for both SARS-CoV-2 test (RT-PCR and N-blinding antibody) during study and had no other protocol deviations determined by clinician. Here, \"N\"= participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Unit per milliliter",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 2",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: EU Lot",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"Pooled US Lots",
                            "OutcomeGroupDescription":"Participants randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1 + US Lot 2 + US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"160"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"945"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"6098.6",
                                        "OutcomeMeasurementLowerLimit":"5474.7",
                                        "OutcomeMeasurementUpperLimit":"6793.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6428.8",
                                        "OutcomeMeasurementLowerLimit":"6149.5",
                                        "OutcomeMeasurementUpperLimit":"6720.7"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeAnalysisList":{
                        "OutcomeAnalysis":[
                          {
                            "OutcomeAnalysisGroupIdList":{
                              "OutcomeAnalysisGroupId":[
                                "OG000",
                                "OG001"
                              ]
                            },
                            "OutcomeAnalysisNonInferiorityType":"Equivalence",
                            "OutcomeAnalysisNonInferiorityComment":"Equivalence was to be achieved if the 2-sided 95% CI for GMR falls within the interval (0.67, 1.5).",
                            "OutcomeAnalysisParamType":"Geometric mean ratio",
                            "OutcomeAnalysisParamValue":"0.95",
                            "OutcomeAnalysisCIPctValue":"95",
                            "OutcomeAnalysisCINumSides":"2-Sided",
                            "OutcomeAnalysisCILowerLimit":"0.84",
                            "OutcomeAnalysisCIUpperLimit":"1.07",
                            "OutcomeAnalysisEstimateComment":"GMRs and corresponding 2-sided 95% CIs were calculated by exponentiating difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of age and vaccine group."
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Ratios (GMRs) of SARS-CoV-2 Neutralizing Titers Between 20-microgram Dose and 30-microgram Dose at 1 Month After Dose 2: Primary Study",
                      "OutcomeMeasureDescription":"Geometric mean titer for SARS-CoV-2 neutralizing titers for 20 mcg dose and 30 mcg dose of US Lot 1 was determined and reported in the descriptive section. GMTs and 2-sided 95% CIs were calculated by exponentiating the least square (LS) mean of the titers and corresponding CIs based on linear regression model. Assay results below the LLOQ were set to 0.5*LLOQ. GMRs were reported in the statistical analysis section and were calculated as the ratio of geometric mean titer of the 20-mcg dose (US Lot 1) to the geometric mean titer of the 30 mcg dose (US Lot 1).",
                      "OutcomeMeasurePopulationDescription":"Evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, with Dose 2 received within predefined window, had at least 1 valid immunogenicity result from blood sample collected within an appropriate window at 1 month after Dose 2, were negative for both SARS-CoV-2 test (RT-PCR and N-blinding antibody) during study and had no other protocol deviations determined by clinician. Here, \"N\"= participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Titer",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 2",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 microgram (mcg) intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"318"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"324"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"906.3",
                                        "OutcomeMeasurementLowerLimit":"847.8",
                                        "OutcomeMeasurementUpperLimit":"968.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"976.6",
                                        "OutcomeMeasurementLowerLimit":"914.1",
                                        "OutcomeMeasurementUpperLimit":"1043.4"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeAnalysisList":{
                        "OutcomeAnalysis":[
                          {
                            "OutcomeAnalysisGroupIdList":{
                              "OutcomeAnalysisGroupId":[
                                "OG000",
                                "OG001"
                              ]
                            },
                            "OutcomeAnalysisNonInferiorityType":"Non-Inferiority",
                            "OutcomeAnalysisNonInferiorityComment":"Noninferiority of the 20 mcg dose to the corresponding 30 mcg dose was said to be achieved if the lower limit of the 2-sided 95% CI for the GMR is >0.67.",
                            "OutcomeAnalysisParamType":"Geometric Mean Ratio",
                            "OutcomeAnalysisParamValue":"0.93",
                            "OutcomeAnalysisCIPctValue":"95",
                            "OutcomeAnalysisCINumSides":"2-Sided",
                            "OutcomeAnalysisCILowerLimit":"0.84",
                            "OutcomeAnalysisCIUpperLimit":"1.02",
                            "OutcomeAnalysisEstimateComment":"GMRs were calculated by exponentiating the difference in LS means and corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model with terms of age and vaccine group"
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study",
                      "OutcomeMeasureDescription":"Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 1. Redness, swelling, and pain at injection site after Dose 1 were reported.",
                      "OutcomeMeasurePopulationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\"= participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"Within 7 days after Dose 1",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG002",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG003",
                            "OutcomeGroupTitle":"Pooled US Lots",
                            "OutcomeGroupDescription":"Participants randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1 + US Lot 2 + US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG004",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: EU Lot",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG005",
                            "OutcomeGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"351"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"352"
                                },{
                                  "OutcomeDenomCountGroupId":"OG002",
                                  "OutcomeDenomCountValue":"345"
                                },{
                                  "OutcomeDenomCountGroupId":"OG003",
                                  "OutcomeDenomCountValue":"1048"
                                },{
                                  "OutcomeDenomCountGroupId":"OG004",
                                  "OutcomeDenomCountValue":"173"
                                },{
                                  "OutcomeDenomCountGroupId":"OG005",
                                  "OutcomeDenomCountValue":"351"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"Redness",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"1.1",
                                        "OutcomeMeasurementLowerLimit":"0.3",
                                        "OutcomeMeasurementUpperLimit":"2.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"2.0",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"2.9",
                                        "OutcomeMeasurementLowerLimit":"1.4",
                                        "OutcomeMeasurementUpperLimit":"5.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"2.0",
                                        "OutcomeMeasurementLowerLimit":"1.2",
                                        "OutcomeMeasurementUpperLimit":"3.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"2.3",
                                        "OutcomeMeasurementLowerLimit":"0.6",
                                        "OutcomeMeasurementUpperLimit":"5.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"2.0",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Swelling",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"2.0",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"3.7",
                                        "OutcomeMeasurementLowerLimit":"2.0",
                                        "OutcomeMeasurementUpperLimit":"6.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"3.8",
                                        "OutcomeMeasurementLowerLimit":"2.0",
                                        "OutcomeMeasurementUpperLimit":"6.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"3.1",
                                        "OutcomeMeasurementLowerLimit":"2.2",
                                        "OutcomeMeasurementUpperLimit":"4.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"2.9",
                                        "OutcomeMeasurementLowerLimit":"0.9",
                                        "OutcomeMeasurementUpperLimit":"6.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"3.4",
                                        "OutcomeMeasurementLowerLimit":"1.8",
                                        "OutcomeMeasurementUpperLimit":"5.9"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Pain at Injection Site",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"82.9",
                                        "OutcomeMeasurementLowerLimit":"78.6",
                                        "OutcomeMeasurementUpperLimit":"86.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"79.3",
                                        "OutcomeMeasurementLowerLimit":"74.6",
                                        "OutcomeMeasurementUpperLimit":"83.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"84.6",
                                        "OutcomeMeasurementLowerLimit":"80.4",
                                        "OutcomeMeasurementUpperLimit":"88.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"82.3",
                                        "OutcomeMeasurementLowerLimit":"79.8",
                                        "OutcomeMeasurementUpperLimit":"84.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"86.1",
                                        "OutcomeMeasurementLowerLimit":"80.1",
                                        "OutcomeMeasurementUpperLimit":"90.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"78.1",
                                        "OutcomeMeasurementLowerLimit":"73.4",
                                        "OutcomeMeasurementUpperLimit":"82.3"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Primary Study",
                      "OutcomeMeasureDescription":"Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 2. Redness, swelling, and pain at injection site after Dose 2 were reported.",
                      "OutcomeMeasurePopulationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\"= participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"Within 7 days after Dose 2",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG002",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG003",
                            "OutcomeGroupTitle":"Pooled US Lots",
                            "OutcomeGroupDescription":"Participants randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1 + US Lot 2 + US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG004",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: EU Lot",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG005",
                            "OutcomeGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"349"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"350"
                                },{
                                  "OutcomeDenomCountGroupId":"OG002",
                                  "OutcomeDenomCountValue":"343"
                                },{
                                  "OutcomeDenomCountGroupId":"OG003",
                                  "OutcomeDenomCountValue":"1042"
                                },{
                                  "OutcomeDenomCountGroupId":"OG004",
                                  "OutcomeDenomCountValue":"172"
                                },{
                                  "OutcomeDenomCountGroupId":"OG005",
                                  "OutcomeDenomCountValue":"348"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"Redness",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"3.7",
                                        "OutcomeMeasurementLowerLimit":"2.0",
                                        "OutcomeMeasurementUpperLimit":"6.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"4.0",
                                        "OutcomeMeasurementLowerLimit":"2.2",
                                        "OutcomeMeasurementUpperLimit":"6.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"4.4",
                                        "OutcomeMeasurementLowerLimit":"2.5",
                                        "OutcomeMeasurementUpperLimit":"7.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"4.0",
                                        "OutcomeMeasurementLowerLimit":"2.9",
                                        "OutcomeMeasurementUpperLimit":"5.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"2.9",
                                        "OutcomeMeasurementLowerLimit":"1.0",
                                        "OutcomeMeasurementUpperLimit":"6.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"3.2",
                                        "OutcomeMeasurementLowerLimit":"1.6",
                                        "OutcomeMeasurementUpperLimit":"5.6"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Swelling",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"4.9",
                                        "OutcomeMeasurementLowerLimit":"2.9",
                                        "OutcomeMeasurementUpperLimit":"7.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6.0",
                                        "OutcomeMeasurementLowerLimit":"3.8",
                                        "OutcomeMeasurementUpperLimit":"9.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"4.7",
                                        "OutcomeMeasurementLowerLimit":"2.7",
                                        "OutcomeMeasurementUpperLimit":"7.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"5.2",
                                        "OutcomeMeasurementLowerLimit":"3.9",
                                        "OutcomeMeasurementUpperLimit":"6.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"3.5",
                                        "OutcomeMeasurementLowerLimit":"1.3",
                                        "OutcomeMeasurementUpperLimit":"7.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"3.7",
                                        "OutcomeMeasurementLowerLimit":"2.0",
                                        "OutcomeMeasurementUpperLimit":"6.3"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Pain at Injection Site",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"80.2",
                                        "OutcomeMeasurementLowerLimit":"75.7",
                                        "OutcomeMeasurementUpperLimit":"84.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"77.7",
                                        "OutcomeMeasurementLowerLimit":"73.0",
                                        "OutcomeMeasurementUpperLimit":"82.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"83.1",
                                        "OutcomeMeasurementLowerLimit":"78.7",
                                        "OutcomeMeasurementUpperLimit":"86.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"80.3",
                                        "OutcomeMeasurementLowerLimit":"77.8",
                                        "OutcomeMeasurementUpperLimit":"82.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"77.3",
                                        "OutcomeMeasurementLowerLimit":"70.3",
                                        "OutcomeMeasurementUpperLimit":"83.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"79.6",
                                        "OutcomeMeasurementLowerLimit":"75.0",
                                        "OutcomeMeasurementUpperLimit":"83.7"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Local Reactions Within 7 Days After Any Dose: Primary Study",
                      "OutcomeMeasureDescription":"Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination. Redness, swelling, and pain at injection site after any dose were reported.",
                      "OutcomeMeasurePopulationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. 1 participant randomized to US Lot 1 was administered US Lot 1 for Dose 1 and US Lot 3 for Dose 2, therefore, the participant was included in both reporting groups (US Lot 1 and US Lot 3).",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"Within 7 days after any dose",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG002",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG003",
                            "OutcomeGroupTitle":"Pooled US Lots",
                            "OutcomeGroupDescription":"Participants randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1 + US Lot 2 + US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG004",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: EU Lot",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG005",
                            "OutcomeGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"351"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"352"
                                },{
                                  "OutcomeDenomCountGroupId":"OG002",
                                  "OutcomeDenomCountValue":"347"
                                },{
                                  "OutcomeDenomCountGroupId":"OG003",
                                  "OutcomeDenomCountValue":"1049"
                                },{
                                  "OutcomeDenomCountGroupId":"OG004",
                                  "OutcomeDenomCountValue":"173"
                                },{
                                  "OutcomeDenomCountGroupId":"OG005",
                                  "OutcomeDenomCountValue":"351"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"Redness",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"4.6",
                                        "OutcomeMeasurementLowerLimit":"2.6",
                                        "OutcomeMeasurementUpperLimit":"7.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"5.4",
                                        "OutcomeMeasurementLowerLimit":"3.3",
                                        "OutcomeMeasurementUpperLimit":"8.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"6.6",
                                        "OutcomeMeasurementLowerLimit":"4.2",
                                        "OutcomeMeasurementUpperLimit":"9.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"5.5",
                                        "OutcomeMeasurementLowerLimit":"4.2",
                                        "OutcomeMeasurementUpperLimit":"7.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"4.6",
                                        "OutcomeMeasurementLowerLimit":"2.0",
                                        "OutcomeMeasurementUpperLimit":"8.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"4.6",
                                        "OutcomeMeasurementLowerLimit":"2.6",
                                        "OutcomeMeasurementUpperLimit":"7.3"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Swelling",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"6.0",
                                        "OutcomeMeasurementLowerLimit":"3.7",
                                        "OutcomeMeasurementUpperLimit":"9.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"8.8",
                                        "OutcomeMeasurementLowerLimit":"6.1",
                                        "OutcomeMeasurementUpperLimit":"12.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"7.2",
                                        "OutcomeMeasurementLowerLimit":"4.7",
                                        "OutcomeMeasurementUpperLimit":"10.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"7.3",
                                        "OutcomeMeasurementLowerLimit":"5.8",
                                        "OutcomeMeasurementUpperLimit":"9.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"4.6",
                                        "OutcomeMeasurementLowerLimit":"2.0",
                                        "OutcomeMeasurementUpperLimit":"8.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"6.3",
                                        "OutcomeMeasurementLowerLimit":"4.0",
                                        "OutcomeMeasurementUpperLimit":"9.3"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Pain at Injection Site",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"90.9",
                                        "OutcomeMeasurementLowerLimit":"87.4",
                                        "OutcomeMeasurementUpperLimit":"93.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"85.8",
                                        "OutcomeMeasurementLowerLimit":"81.7",
                                        "OutcomeMeasurementUpperLimit":"89.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"91.1",
                                        "OutcomeMeasurementLowerLimit":"87.6",
                                        "OutcomeMeasurementUpperLimit":"93.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"89.2",
                                        "OutcomeMeasurementLowerLimit":"87.2",
                                        "OutcomeMeasurementUpperLimit":"91.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"91.3",
                                        "OutcomeMeasurementLowerLimit":"86.1",
                                        "OutcomeMeasurementUpperLimit":"95.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"89.5",
                                        "OutcomeMeasurementLowerLimit":"85.8",
                                        "OutcomeMeasurementUpperLimit":"92.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 3. Redness, swelling, and pain at injection site after Dose 3 were reported.",
                      "OutcomeMeasurePopulationDescription":"Safety population included all randomized participants who received dose 3 of the study intervention.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"Within 7 days after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"31"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"31"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"Redness",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"9.7",
                                        "OutcomeMeasurementSpread":"2.0",
                                        "OutcomeMeasurementLowerLimit":"2.0",
                                        "OutcomeMeasurementUpperLimit":"25.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"3.2",
                                        "OutcomeMeasurementSpread":"0.1",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"16.7"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Swelling",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"6.5",
                                        "OutcomeMeasurementSpread":"0.8",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"21.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6.5",
                                        "OutcomeMeasurementSpread":"0.8",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"21.4"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Pain at Injection site",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"90.3",
                                        "OutcomeMeasurementSpread":"74.2",
                                        "OutcomeMeasurementLowerLimit":"74.2",
                                        "OutcomeMeasurementUpperLimit":"98.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"93.5",
                                        "OutcomeMeasurementSpread":"78.6",
                                        "OutcomeMeasurementLowerLimit":"78.6",
                                        "OutcomeMeasurementUpperLimit":"99.2"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Primary Study",
                      "OutcomeMeasureDescription":"Systemic events were reported using an electronic diary. Fever was defined as temperature >=38.0 degree Celsius (C) and categorized as >=38.0 to 38.4 C; >38.4 to 38.9 C; >38.9 to 40.0 C; >40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 1 were reported.",
                      "OutcomeMeasurePopulationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\"= participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"Within 7 days after Dose 1",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG002",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG003",
                            "OutcomeGroupTitle":"Pooled US Lots",
                            "OutcomeGroupDescription":"Participants randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1 + US Lot 2 + US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG004",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: EU Lot",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG005",
                            "OutcomeGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"351"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"352"
                                },{
                                  "OutcomeDenomCountGroupId":"OG002",
                                  "OutcomeDenomCountValue":"345"
                                },{
                                  "OutcomeDenomCountGroupId":"OG003",
                                  "OutcomeDenomCountValue":"1048"
                                },{
                                  "OutcomeDenomCountGroupId":"OG004",
                                  "OutcomeDenomCountValue":"173"
                                },{
                                  "OutcomeDenomCountGroupId":"OG005",
                                  "OutcomeDenomCountValue":"351"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"Fever >=38.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0.3",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"2.0",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"0.8",
                                        "OutcomeMeasurementLowerLimit":"0.3",
                                        "OutcomeMeasurementUpperLimit":"1.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"1.2",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >=38.0 C to 38.4 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0.3",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"1.2",
                                        "OutcomeMeasurementLowerLimit":"0.3",
                                        "OutcomeMeasurementUpperLimit":"2.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"0.5",
                                        "OutcomeMeasurementLowerLimit":"0.2",
                                        "OutcomeMeasurementUpperLimit":"1.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"0.6",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"3.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >38.4 C to 38.9 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"0.6",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"2.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"0.2",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"0.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"0.6",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"3.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >38.9 C to 40.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"0.3",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"0.1",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"0.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"2.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >40.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"1",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"0.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"2.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fatigue",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"53.3",
                                        "OutcomeMeasurementLowerLimit":"47.9",
                                        "OutcomeMeasurementUpperLimit":"58.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"45.5",
                                        "OutcomeMeasurementLowerLimit":"40.2",
                                        "OutcomeMeasurementUpperLimit":"50.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"50.7",
                                        "OutcomeMeasurementLowerLimit":"45.3",
                                        "OutcomeMeasurementUpperLimit":"56.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"49.8",
                                        "OutcomeMeasurementLowerLimit":"46.7",
                                        "OutcomeMeasurementUpperLimit":"52.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"49.1",
                                        "OutcomeMeasurementLowerLimit":"41.5",
                                        "OutcomeMeasurementUpperLimit":"56.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"49.0",
                                        "OutcomeMeasurementLowerLimit":"43.7",
                                        "OutcomeMeasurementUpperLimit":"54.4"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Headache",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"36.2",
                                        "OutcomeMeasurementLowerLimit":"31.1",
                                        "OutcomeMeasurementUpperLimit":"41.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"32.7",
                                        "OutcomeMeasurementLowerLimit":"27.8",
                                        "OutcomeMeasurementUpperLimit":"37.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"33.3",
                                        "OutcomeMeasurementLowerLimit":"28.4",
                                        "OutcomeMeasurementUpperLimit":"38.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"34.1",
                                        "OutcomeMeasurementLowerLimit":"31.2",
                                        "OutcomeMeasurementUpperLimit":"37.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"38.7",
                                        "OutcomeMeasurementLowerLimit":"31.4",
                                        "OutcomeMeasurementUpperLimit":"46.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"35.6",
                                        "OutcomeMeasurementLowerLimit":"30.6",
                                        "OutcomeMeasurementUpperLimit":"40.9"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Chills",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"8.5",
                                        "OutcomeMeasurementLowerLimit":"5.8",
                                        "OutcomeMeasurementUpperLimit":"12.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"7.7",
                                        "OutcomeMeasurementLowerLimit":"5.1",
                                        "OutcomeMeasurementUpperLimit":"11.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"10.1",
                                        "OutcomeMeasurementLowerLimit":"7.2",
                                        "OutcomeMeasurementUpperLimit":"13.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"8.8",
                                        "OutcomeMeasurementLowerLimit":"7.1",
                                        "OutcomeMeasurementUpperLimit":"10.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"8.1",
                                        "OutcomeMeasurementLowerLimit":"4.5",
                                        "OutcomeMeasurementUpperLimit":"13.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"6.8",
                                        "OutcomeMeasurementLowerLimit":"4.4",
                                        "OutcomeMeasurementUpperLimit":"10.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Vomiting",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0.6",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"2.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0.6",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"2.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"1.2",
                                        "OutcomeMeasurementLowerLimit":"0.3",
                                        "OutcomeMeasurementUpperLimit":"2.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"0.8",
                                        "OutcomeMeasurementLowerLimit":"0.3",
                                        "OutcomeMeasurementUpperLimit":"1.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"0.6",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"3.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"0.9",
                                        "OutcomeMeasurementLowerLimit":"0.2",
                                        "OutcomeMeasurementUpperLimit":"2.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Diarrhea",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"9.7",
                                        "OutcomeMeasurementLowerLimit":"6.8",
                                        "OutcomeMeasurementUpperLimit":"13.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"8.0",
                                        "OutcomeMeasurementLowerLimit":"5.4",
                                        "OutcomeMeasurementUpperLimit":"11.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"7.8",
                                        "OutcomeMeasurementLowerLimit":"5.2",
                                        "OutcomeMeasurementUpperLimit":"11.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"8.5",
                                        "OutcomeMeasurementLowerLimit":"6.9",
                                        "OutcomeMeasurementUpperLimit":"10.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"9.2",
                                        "OutcomeMeasurementLowerLimit":"5.4",
                                        "OutcomeMeasurementUpperLimit":"14.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"10.0",
                                        "OutcomeMeasurementLowerLimit":"7.0",
                                        "OutcomeMeasurementUpperLimit":"13.6"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"New/worsened muscle pain",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"14.5",
                                        "OutcomeMeasurementLowerLimit":"11.0",
                                        "OutcomeMeasurementUpperLimit":"18.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"13.1",
                                        "OutcomeMeasurementLowerLimit":"9.7",
                                        "OutcomeMeasurementUpperLimit":"17.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"16.5",
                                        "OutcomeMeasurementLowerLimit":"12.8",
                                        "OutcomeMeasurementUpperLimit":"20.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"14.7",
                                        "OutcomeMeasurementLowerLimit":"12.6",
                                        "OutcomeMeasurementUpperLimit":"17.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"17.3",
                                        "OutcomeMeasurementLowerLimit":"12.0",
                                        "OutcomeMeasurementUpperLimit":"23.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"16.2",
                                        "OutcomeMeasurementLowerLimit":"12.5",
                                        "OutcomeMeasurementUpperLimit":"20.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"New/worsened joint pain",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"6.8",
                                        "OutcomeMeasurementLowerLimit":"4.4",
                                        "OutcomeMeasurementUpperLimit":"10.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6.5",
                                        "OutcomeMeasurementLowerLimit":"4.2",
                                        "OutcomeMeasurementUpperLimit":"9.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"7.0",
                                        "OutcomeMeasurementLowerLimit":"4.5",
                                        "OutcomeMeasurementUpperLimit":"10.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"6.8",
                                        "OutcomeMeasurementLowerLimit":"5.3",
                                        "OutcomeMeasurementUpperLimit":"8.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"7.5",
                                        "OutcomeMeasurementLowerLimit":"4.1",
                                        "OutcomeMeasurementUpperLimit":"12.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"6.6",
                                        "OutcomeMeasurementLowerLimit":"4.2",
                                        "OutcomeMeasurementUpperLimit":"9.7"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Use of antipyretic/analgesic medication",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"16.8",
                                        "OutcomeMeasurementLowerLimit":"13.0",
                                        "OutcomeMeasurementUpperLimit":"21.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"14.5",
                                        "OutcomeMeasurementLowerLimit":"11.0",
                                        "OutcomeMeasurementUpperLimit":"18.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"18.8",
                                        "OutcomeMeasurementLowerLimit":"14.9",
                                        "OutcomeMeasurementUpperLimit":"23.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"16.7",
                                        "OutcomeMeasurementLowerLimit":"14.5",
                                        "OutcomeMeasurementUpperLimit":"19.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"22.0",
                                        "OutcomeMeasurementLowerLimit":"16.0",
                                        "OutcomeMeasurementUpperLimit":"28.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"18.2",
                                        "OutcomeMeasurementLowerLimit":"14.3",
                                        "OutcomeMeasurementUpperLimit":"22.7"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Primary Study",
                      "OutcomeMeasureDescription":"Systemic events were reported using an electronic diary. Fever was defined as temperature >=38.0 C and categorized as >=38.0 to 38.4 C; >38.4 to 38.9 C; >38.9 to 40.0 C; >40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 2 were reported.",
                      "OutcomeMeasurePopulationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. Here, \"Overall Number of Participants Analyzed\"= participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"Within 7 days after Dose 2",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG002",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG003",
                            "OutcomeGroupTitle":"Pooled US Lots",
                            "OutcomeGroupDescription":"Participants randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1 + US Lot 2 + US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG004",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: EU Lot",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG005",
                            "OutcomeGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"349"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"350"
                                },{
                                  "OutcomeDenomCountGroupId":"OG002",
                                  "OutcomeDenomCountValue":"343"
                                },{
                                  "OutcomeDenomCountGroupId":"OG003",
                                  "OutcomeDenomCountValue":"1042"
                                },{
                                  "OutcomeDenomCountGroupId":"OG004",
                                  "OutcomeDenomCountValue":"172"
                                },{
                                  "OutcomeDenomCountGroupId":"OG005",
                                  "OutcomeDenomCountValue":"348"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"Fever >=38.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"7.2",
                                        "OutcomeMeasurementLowerLimit":"4.7",
                                        "OutcomeMeasurementUpperLimit":"10.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6.3",
                                        "OutcomeMeasurementLowerLimit":"4.0",
                                        "OutcomeMeasurementUpperLimit":"9.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"6.7",
                                        "OutcomeMeasurementLowerLimit":"4.3",
                                        "OutcomeMeasurementUpperLimit":"9.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"6.7",
                                        "OutcomeMeasurementLowerLimit":"5.3",
                                        "OutcomeMeasurementUpperLimit":"8.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"8.7",
                                        "OutcomeMeasurementLowerLimit":"5.0",
                                        "OutcomeMeasurementUpperLimit":"14.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"5.7",
                                        "OutcomeMeasurementLowerLimit":"3.5",
                                        "OutcomeMeasurementUpperLimit":"8.7"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >=38.0 C to 38.4 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"4.6",
                                        "OutcomeMeasurementLowerLimit":"2.6",
                                        "OutcomeMeasurementUpperLimit":"7.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"3.4",
                                        "OutcomeMeasurementLowerLimit":"1.8",
                                        "OutcomeMeasurementUpperLimit":"5.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"3.2",
                                        "OutcomeMeasurementLowerLimit":"1.6",
                                        "OutcomeMeasurementUpperLimit":"5.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"3.7",
                                        "OutcomeMeasurementLowerLimit":"2.7",
                                        "OutcomeMeasurementUpperLimit":"5.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"6.4",
                                        "OutcomeMeasurementLowerLimit":"3.2",
                                        "OutcomeMeasurementUpperLimit":"11.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"4.3",
                                        "OutcomeMeasurementLowerLimit":"2.4",
                                        "OutcomeMeasurementUpperLimit":"7.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >38.4 C to 38.9 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"2.0",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"2.0",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"2.3",
                                        "OutcomeMeasurementLowerLimit":"1.0",
                                        "OutcomeMeasurementUpperLimit":"4.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"2.1",
                                        "OutcomeMeasurementLowerLimit":"1.3",
                                        "OutcomeMeasurementUpperLimit":"3.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"1.2",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"1.4",
                                        "OutcomeMeasurementLowerLimit":"0.5",
                                        "OutcomeMeasurementUpperLimit":"3.3"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >38.9 C to 40.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0.6",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"2.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0.9",
                                        "OutcomeMeasurementLowerLimit":"0.2",
                                        "OutcomeMeasurementUpperLimit":"2.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"0.9",
                                        "OutcomeMeasurementLowerLimit":"0.2",
                                        "OutcomeMeasurementUpperLimit":"2.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"0.8",
                                        "OutcomeMeasurementLowerLimit":"0.3",
                                        "OutcomeMeasurementUpperLimit":"1.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"1.2",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.1"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >40.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"0.3",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"0.1",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"0.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"2.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"2.1"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fatigue",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"69.9",
                                        "OutcomeMeasurementLowerLimit":"64.8",
                                        "OutcomeMeasurementUpperLimit":"74.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"66.6",
                                        "OutcomeMeasurementLowerLimit":"61.4",
                                        "OutcomeMeasurementUpperLimit":"71.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"71.4",
                                        "OutcomeMeasurementLowerLimit":"66.3",
                                        "OutcomeMeasurementUpperLimit":"76.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"69.3",
                                        "OutcomeMeasurementLowerLimit":"66.4",
                                        "OutcomeMeasurementUpperLimit":"72.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"69.8",
                                        "OutcomeMeasurementLowerLimit":"62.3",
                                        "OutcomeMeasurementUpperLimit":"76.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"66.7",
                                        "OutcomeMeasurementLowerLimit":"61.4",
                                        "OutcomeMeasurementUpperLimit":"71.6"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Headache",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"57.0",
                                        "OutcomeMeasurementLowerLimit":"51.6",
                                        "OutcomeMeasurementUpperLimit":"62.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"56.6",
                                        "OutcomeMeasurementLowerLimit":"51.2",
                                        "OutcomeMeasurementUpperLimit":"61.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"56.9",
                                        "OutcomeMeasurementLowerLimit":"51.4",
                                        "OutcomeMeasurementUpperLimit":"62.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"56.8",
                                        "OutcomeMeasurementLowerLimit":"53.7",
                                        "OutcomeMeasurementUpperLimit":"59.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"56.4",
                                        "OutcomeMeasurementLowerLimit":"48.6",
                                        "OutcomeMeasurementUpperLimit":"63.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"50.6",
                                        "OutcomeMeasurementLowerLimit":"45.2",
                                        "OutcomeMeasurementUpperLimit":"55.9"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Chills",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"28.1",
                                        "OutcomeMeasurementLowerLimit":"23.4",
                                        "OutcomeMeasurementUpperLimit":"33.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"31.1",
                                        "OutcomeMeasurementLowerLimit":"26.3",
                                        "OutcomeMeasurementUpperLimit":"36.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"33.8",
                                        "OutcomeMeasurementLowerLimit":"28.8",
                                        "OutcomeMeasurementUpperLimit":"39.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"31.0",
                                        "OutcomeMeasurementLowerLimit":"28.2",
                                        "OutcomeMeasurementUpperLimit":"33.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"28.5",
                                        "OutcomeMeasurementLowerLimit":"21.9",
                                        "OutcomeMeasurementUpperLimit":"35.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"23.6",
                                        "OutcomeMeasurementLowerLimit":"19.2",
                                        "OutcomeMeasurementUpperLimit":"28.4"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Vomiting",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"2.3",
                                        "OutcomeMeasurementLowerLimit":"1.0",
                                        "OutcomeMeasurementUpperLimit":"4.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"1.4",
                                        "OutcomeMeasurementLowerLimit":"0.5",
                                        "OutcomeMeasurementUpperLimit":"3.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"2.3",
                                        "OutcomeMeasurementLowerLimit":"1.0",
                                        "OutcomeMeasurementUpperLimit":"4.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"2.0",
                                        "OutcomeMeasurementLowerLimit":"1.3",
                                        "OutcomeMeasurementUpperLimit":"3.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"1.7",
                                        "OutcomeMeasurementLowerLimit":"0.4",
                                        "OutcomeMeasurementUpperLimit":"5.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"1.4",
                                        "OutcomeMeasurementLowerLimit":"0.5",
                                        "OutcomeMeasurementUpperLimit":"3.3"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Diarrhea",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"8.3",
                                        "OutcomeMeasurementLowerLimit":"5.6",
                                        "OutcomeMeasurementUpperLimit":"11.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"9.1",
                                        "OutcomeMeasurementLowerLimit":"6.3",
                                        "OutcomeMeasurementUpperLimit":"12.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"7.9",
                                        "OutcomeMeasurementLowerLimit":"5.3",
                                        "OutcomeMeasurementUpperLimit":"11.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"8.4",
                                        "OutcomeMeasurementLowerLimit":"6.8",
                                        "OutcomeMeasurementUpperLimit":"10.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"9.3",
                                        "OutcomeMeasurementLowerLimit":"5.4",
                                        "OutcomeMeasurementUpperLimit":"14.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"6.9",
                                        "OutcomeMeasurementLowerLimit":"4.5",
                                        "OutcomeMeasurementUpperLimit":"10.1"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"New/worsened muscle pain",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"32.7",
                                        "OutcomeMeasurementLowerLimit":"27.8",
                                        "OutcomeMeasurementUpperLimit":"37.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"38.6",
                                        "OutcomeMeasurementLowerLimit":"33.4",
                                        "OutcomeMeasurementUpperLimit":"43.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"35.6",
                                        "OutcomeMeasurementLowerLimit":"30.5",
                                        "OutcomeMeasurementUpperLimit":"40.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"35.6",
                                        "OutcomeMeasurementLowerLimit":"32.7",
                                        "OutcomeMeasurementUpperLimit":"38.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"36.0",
                                        "OutcomeMeasurementLowerLimit":"28.9",
                                        "OutcomeMeasurementUpperLimit":"43.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"35.6",
                                        "OutcomeMeasurementLowerLimit":"30.6",
                                        "OutcomeMeasurementUpperLimit":"40.9"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"New/worsened joint pain",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"19.2",
                                        "OutcomeMeasurementLowerLimit":"15.2",
                                        "OutcomeMeasurementUpperLimit":"23.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"24.6",
                                        "OutcomeMeasurementLowerLimit":"20.2",
                                        "OutcomeMeasurementUpperLimit":"29.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"19.2",
                                        "OutcomeMeasurementLowerLimit":"15.2",
                                        "OutcomeMeasurementUpperLimit":"23.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"21.0",
                                        "OutcomeMeasurementLowerLimit":"18.6",
                                        "OutcomeMeasurementUpperLimit":"23.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"19.2",
                                        "OutcomeMeasurementLowerLimit":"13.6",
                                        "OutcomeMeasurementUpperLimit":"25.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"19.5",
                                        "OutcomeMeasurementLowerLimit":"15.5",
                                        "OutcomeMeasurementUpperLimit":"24.1"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Use of antipyretic/analgesic medication",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"35.2",
                                        "OutcomeMeasurementLowerLimit":"30.2",
                                        "OutcomeMeasurementUpperLimit":"40.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"41.1",
                                        "OutcomeMeasurementLowerLimit":"35.9",
                                        "OutcomeMeasurementUpperLimit":"46.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"40.8",
                                        "OutcomeMeasurementLowerLimit":"35.6",
                                        "OutcomeMeasurementUpperLimit":"46.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"39.1",
                                        "OutcomeMeasurementLowerLimit":"36.1",
                                        "OutcomeMeasurementUpperLimit":"42.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"41.9",
                                        "OutcomeMeasurementLowerLimit":"34.4",
                                        "OutcomeMeasurementUpperLimit":"49.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"37.9",
                                        "OutcomeMeasurementLowerLimit":"32.8",
                                        "OutcomeMeasurementUpperLimit":"43.3"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Systemic Events Within 7 Days After Any Dose: Primary Study",
                      "OutcomeMeasureDescription":"Systemic events were reported using an electronic diary. Fever was defined as temperature >=38.0 C and categorized as >=38.0 to 38.4 C; >38.4 to 38.9 C; >38.9 to 40.0 C; >40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after any dose were reported.",
                      "OutcomeMeasurePopulationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention. 1 participant randomized to US Lot 1 was administered US Lot 1 for Dose 1 and US Lot 3 for Dose 2, therefore, the participant was included in both reporting groups (US Lot 1 and US Lot 3).",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"Within 7 days after any dose",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG002",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG003",
                            "OutcomeGroupTitle":"Pooled US Lots",
                            "OutcomeGroupDescription":"Participants randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1 + US Lot 2 + US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG004",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: EU Lot",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG005",
                            "OutcomeGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"351"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"352"
                                },{
                                  "OutcomeDenomCountGroupId":"OG002",
                                  "OutcomeDenomCountValue":"347"
                                },{
                                  "OutcomeDenomCountGroupId":"OG003",
                                  "OutcomeDenomCountValue":"1049"
                                },{
                                  "OutcomeDenomCountGroupId":"OG004",
                                  "OutcomeDenomCountValue":"173"
                                },{
                                  "OutcomeDenomCountGroupId":"OG005",
                                  "OutcomeDenomCountValue":"351"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"Fever >=38.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"7.4",
                                        "OutcomeMeasurementLowerLimit":"4.9",
                                        "OutcomeMeasurementUpperLimit":"10.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6.3",
                                        "OutcomeMeasurementLowerLimit":"4.0",
                                        "OutcomeMeasurementUpperLimit":"9.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"8.4",
                                        "OutcomeMeasurementLowerLimit":"5.7",
                                        "OutcomeMeasurementUpperLimit":"11.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"7.3",
                                        "OutcomeMeasurementLowerLimit":"5.8",
                                        "OutcomeMeasurementUpperLimit":"9.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"9.2",
                                        "OutcomeMeasurementLowerLimit":"5.4",
                                        "OutcomeMeasurementUpperLimit":"14.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"5.7",
                                        "OutcomeMeasurementLowerLimit":"3.5",
                                        "OutcomeMeasurementUpperLimit":"8.7"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >=38.0 C to 38.4 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"4.8",
                                        "OutcomeMeasurementLowerLimit":"2.8",
                                        "OutcomeMeasurementUpperLimit":"7.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"3.4",
                                        "OutcomeMeasurementLowerLimit":"1.8",
                                        "OutcomeMeasurementUpperLimit":"5.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"4.0",
                                        "OutcomeMeasurementLowerLimit":"2.2",
                                        "OutcomeMeasurementUpperLimit":"6.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"4.1",
                                        "OutcomeMeasurementLowerLimit":"3.0",
                                        "OutcomeMeasurementUpperLimit":"5.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"6.4",
                                        "OutcomeMeasurementLowerLimit":"3.2",
                                        "OutcomeMeasurementUpperLimit":"11.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"4.3",
                                        "OutcomeMeasurementLowerLimit":"2.4",
                                        "OutcomeMeasurementUpperLimit":"7.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >38.4 C to 38.9 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"2.0",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"2.0",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"2.9",
                                        "OutcomeMeasurementLowerLimit":"1.4",
                                        "OutcomeMeasurementUpperLimit":"5.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"2.3",
                                        "OutcomeMeasurementLowerLimit":"1.5",
                                        "OutcomeMeasurementUpperLimit":"3.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"1.7",
                                        "OutcomeMeasurementLowerLimit":"0.4",
                                        "OutcomeMeasurementUpperLimit":"5.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"1.4",
                                        "OutcomeMeasurementLowerLimit":"0.5",
                                        "OutcomeMeasurementUpperLimit":"3.3"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >38.9 C to 40.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0.6",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"2.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0.9",
                                        "OutcomeMeasurementLowerLimit":"0.2",
                                        "OutcomeMeasurementUpperLimit":"2.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"1.2",
                                        "OutcomeMeasurementLowerLimit":"0.3",
                                        "OutcomeMeasurementUpperLimit":"2.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"0.9",
                                        "OutcomeMeasurementLowerLimit":"0.4",
                                        "OutcomeMeasurementUpperLimit":"1.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"1.2",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >40.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"0.3",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"0.1",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"0.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"2.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"1.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fatigue",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"78.6",
                                        "OutcomeMeasurementLowerLimit":"74.0",
                                        "OutcomeMeasurementUpperLimit":"82.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"73.6",
                                        "OutcomeMeasurementLowerLimit":"68.6",
                                        "OutcomeMeasurementUpperLimit":"78.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"81.0",
                                        "OutcomeMeasurementLowerLimit":"76.4",
                                        "OutcomeMeasurementUpperLimit":"85.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"77.8",
                                        "OutcomeMeasurementLowerLimit":"75.1",
                                        "OutcomeMeasurementUpperLimit":"80.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"76.9",
                                        "OutcomeMeasurementLowerLimit":"69.9",
                                        "OutcomeMeasurementUpperLimit":"82.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"75.5",
                                        "OutcomeMeasurementLowerLimit":"70.7",
                                        "OutcomeMeasurementUpperLimit":"79.9"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Headache",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"66.7",
                                        "OutcomeMeasurementLowerLimit":"61.5",
                                        "OutcomeMeasurementUpperLimit":"71.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"65.1",
                                        "OutcomeMeasurementLowerLimit":"59.8",
                                        "OutcomeMeasurementUpperLimit":"70.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"64.3",
                                        "OutcomeMeasurementLowerLimit":"59.0",
                                        "OutcomeMeasurementUpperLimit":"69.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"65.4",
                                        "OutcomeMeasurementLowerLimit":"62.4",
                                        "OutcomeMeasurementUpperLimit":"68.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"68.8",
                                        "OutcomeMeasurementLowerLimit":"61.3",
                                        "OutcomeMeasurementUpperLimit":"75.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"63.8",
                                        "OutcomeMeasurementLowerLimit":"58.5",
                                        "OutcomeMeasurementUpperLimit":"68.9"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Chills",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"32.8",
                                        "OutcomeMeasurementLowerLimit":"27.9",
                                        "OutcomeMeasurementUpperLimit":"37.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"34.1",
                                        "OutcomeMeasurementLowerLimit":"29.1",
                                        "OutcomeMeasurementUpperLimit":"39.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"37.2",
                                        "OutcomeMeasurementLowerLimit":"32.1",
                                        "OutcomeMeasurementUpperLimit":"42.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"34.7",
                                        "OutcomeMeasurementLowerLimit":"31.8",
                                        "OutcomeMeasurementUpperLimit":"37.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"32.4",
                                        "OutcomeMeasurementLowerLimit":"25.5",
                                        "OutcomeMeasurementUpperLimit":"39.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"26.2",
                                        "OutcomeMeasurementLowerLimit":"21.7",
                                        "OutcomeMeasurementUpperLimit":"31.1"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Vomiting",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"2.8",
                                        "OutcomeMeasurementLowerLimit":"1.4",
                                        "OutcomeMeasurementUpperLimit":"5.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"2.0",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"4.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"3.5",
                                        "OutcomeMeasurementLowerLimit":"1.8",
                                        "OutcomeMeasurementUpperLimit":"6.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"2.8",
                                        "OutcomeMeasurementLowerLimit":"1.9",
                                        "OutcomeMeasurementUpperLimit":"3.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"2.3",
                                        "OutcomeMeasurementLowerLimit":"0.6",
                                        "OutcomeMeasurementUpperLimit":"5.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"2.3",
                                        "OutcomeMeasurementLowerLimit":"1.0",
                                        "OutcomeMeasurementUpperLimit":"4.4"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Diarrhea",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"16.2",
                                        "OutcomeMeasurementLowerLimit":"12.5",
                                        "OutcomeMeasurementUpperLimit":"20.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"14.2",
                                        "OutcomeMeasurementLowerLimit":"10.7",
                                        "OutcomeMeasurementUpperLimit":"18.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"13.8",
                                        "OutcomeMeasurementLowerLimit":"10.4",
                                        "OutcomeMeasurementUpperLimit":"17.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"14.8",
                                        "OutcomeMeasurementLowerLimit":"12.7",
                                        "OutcomeMeasurementUpperLimit":"17.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"15.0",
                                        "OutcomeMeasurementLowerLimit":"10.1",
                                        "OutcomeMeasurementUpperLimit":"21.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"15.4",
                                        "OutcomeMeasurementLowerLimit":"11.8",
                                        "OutcomeMeasurementUpperLimit":"19.6"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"New/worsened muscle pain",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"38.7",
                                        "OutcomeMeasurementLowerLimit":"33.6",
                                        "OutcomeMeasurementUpperLimit":"44.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"43.5",
                                        "OutcomeMeasurementLowerLimit":"38.2",
                                        "OutcomeMeasurementUpperLimit":"48.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"43.2",
                                        "OutcomeMeasurementLowerLimit":"37.9",
                                        "OutcomeMeasurementUpperLimit":"48.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"41.8",
                                        "OutcomeMeasurementLowerLimit":"38.8",
                                        "OutcomeMeasurementUpperLimit":"44.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"43.9",
                                        "OutcomeMeasurementLowerLimit":"36.4",
                                        "OutcomeMeasurementUpperLimit":"51.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"40.5",
                                        "OutcomeMeasurementLowerLimit":"35.3",
                                        "OutcomeMeasurementUpperLimit":"45.8"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"New/worsened joint pain",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"23.4",
                                        "OutcomeMeasurementLowerLimit":"19.0",
                                        "OutcomeMeasurementUpperLimit":"28.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"27.3",
                                        "OutcomeMeasurementLowerLimit":"22.7",
                                        "OutcomeMeasurementUpperLimit":"32.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"23.9",
                                        "OutcomeMeasurementLowerLimit":"19.5",
                                        "OutcomeMeasurementUpperLimit":"28.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"24.9",
                                        "OutcomeMeasurementLowerLimit":"22.3",
                                        "OutcomeMeasurementUpperLimit":"27.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"24.3",
                                        "OutcomeMeasurementLowerLimit":"18.1",
                                        "OutcomeMeasurementUpperLimit":"31.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"22.2",
                                        "OutcomeMeasurementLowerLimit":"18.0",
                                        "OutcomeMeasurementUpperLimit":"26.9"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Use of antipyretic/analgesic medication",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"41.9",
                                        "OutcomeMeasurementLowerLimit":"36.7",
                                        "OutcomeMeasurementUpperLimit":"47.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"43.8",
                                        "OutcomeMeasurementLowerLimit":"38.5",
                                        "OutcomeMeasurementUpperLimit":"49.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"46.4",
                                        "OutcomeMeasurementLowerLimit":"41.1",
                                        "OutcomeMeasurementUpperLimit":"51.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"44.0",
                                        "OutcomeMeasurementLowerLimit":"41.0",
                                        "OutcomeMeasurementUpperLimit":"47.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"51.4",
                                        "OutcomeMeasurementLowerLimit":"43.7",
                                        "OutcomeMeasurementUpperLimit":"59.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"43.6",
                                        "OutcomeMeasurementLowerLimit":"38.3",
                                        "OutcomeMeasurementUpperLimit":"49.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"Systemic events were reported using an electronic diary. Fever was defined as temperature >=38.0 C and categorized as >=38.0 to 38.4 C; >38.4 to 38.9 C; >38.9 to 40.0 C; >40.0 C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, diarrhea, and use of antipyretic/analgesic medication after Dose 3 were reported.",
                      "OutcomeMeasurePopulationDescription":"Safety population included all randomized participants who received dose 3 of the study intervention.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"Within 7 days after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"31"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"31"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"Fever >=38.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"3.2",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"16.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6.5",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"21.4"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >=38.0 C to 38.4 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"11.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6.5",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"21.4"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >38.4 C to 38.9 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"3.2",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"16.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"11.2"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >38.9 C to 40.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"11.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"11.2"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fever >40.0 C",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"11.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"11.2"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Fatigue",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"67.7",
                                        "OutcomeMeasurementLowerLimit":"48.6",
                                        "OutcomeMeasurementUpperLimit":"83.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"83.9",
                                        "OutcomeMeasurementLowerLimit":"66.3",
                                        "OutcomeMeasurementUpperLimit":"94.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Headache",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"41.9",
                                        "OutcomeMeasurementLowerLimit":"24.5",
                                        "OutcomeMeasurementUpperLimit":"60.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"58.1",
                                        "OutcomeMeasurementLowerLimit":"39.1",
                                        "OutcomeMeasurementUpperLimit":"75.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Chills",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"25.8",
                                        "OutcomeMeasurementLowerLimit":"11.9",
                                        "OutcomeMeasurementUpperLimit":"44.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"19.4",
                                        "OutcomeMeasurementLowerLimit":"7.5",
                                        "OutcomeMeasurementUpperLimit":"37.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Vomiting",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"3.2",
                                        "OutcomeMeasurementLowerLimit":"0.1",
                                        "OutcomeMeasurementUpperLimit":"16.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0",
                                        "OutcomeMeasurementLowerLimit":"0.0",
                                        "OutcomeMeasurementUpperLimit":"11.2"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Diarrhea",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"16.1",
                                        "OutcomeMeasurementLowerLimit":"5.5",
                                        "OutcomeMeasurementUpperLimit":"33.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6.5",
                                        "OutcomeMeasurementLowerLimit":"0.8",
                                        "OutcomeMeasurementUpperLimit":"21.4"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"New/worsened muscle pain",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"41.9",
                                        "OutcomeMeasurementLowerLimit":"24.5",
                                        "OutcomeMeasurementUpperLimit":"60.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"19.4",
                                        "OutcomeMeasurementLowerLimit":"7.5",
                                        "OutcomeMeasurementUpperLimit":"37.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"New/worsened joint pain",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"12.9",
                                        "OutcomeMeasurementLowerLimit":"3.6",
                                        "OutcomeMeasurementUpperLimit":"29.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"12.9",
                                        "OutcomeMeasurementLowerLimit":"3.6",
                                        "OutcomeMeasurementUpperLimit":"29.8"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"Use of antipyretic/analgesic medication",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"32.3",
                                        "OutcomeMeasurementLowerLimit":"16.7",
                                        "OutcomeMeasurementUpperLimit":"51.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"35.5",
                                        "OutcomeMeasurementLowerLimit":"19.2",
                                        "OutcomeMeasurementUpperLimit":"54.6"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 2: Primary Study",
                      "OutcomeMeasureDescription":"An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.",
                      "OutcomeMeasurePopulationDescription":"Safety population included all randomized participants who received at least 1 dose of the study intervention.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"Day 1 of Dose 1 up to 1 Month after Dose 2 (for a maximum of 2 months)",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG002",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG003",
                            "OutcomeGroupTitle":"Pooled US Lots",
                            "OutcomeGroupDescription":"Participants randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1 + US Lot 2 + US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG004",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: EU Lot",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG005",
                            "OutcomeGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"351"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"352"
                                },{
                                  "OutcomeDenomCountGroupId":"OG002",
                                  "OutcomeDenomCountValue":"346"
                                },{
                                  "OutcomeDenomCountGroupId":"OG003",
                                  "OutcomeDenomCountValue":"1049"
                                },{
                                  "OutcomeDenomCountGroupId":"OG004",
                                  "OutcomeDenomCountValue":"173"
                                },{
                                  "OutcomeDenomCountGroupId":"OG005",
                                  "OutcomeDenomCountValue":"351"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"AEs",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"5.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"5.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"5.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"10.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"6.8"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"SAEs",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"0.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"0.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"0.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG005",
                                        "OutcomeMeasurementValue":"0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 3 to 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly or that was considered to be an important medical event.",
                      "OutcomeMeasurePopulationDescription":"Safety population included all randomized participants who received Dose 3 of the study intervention.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"From Dose 3 to 1 Month after Dose 3 (for a maximum of 35 days)",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"31"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"31"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"AEs",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"6.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"3.2"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"SAEs",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain at Baseline: Booster Study",
                      "OutcomeMeasureDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Titer",
                      "OutcomeMeasureTimeFrame":"Baseline (prior to Dose 1 of Primary study)",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"25"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"20.5",
                                        "OutcomeMeasurementLowerLimit":"20.5",
                                        "OutcomeMeasurementUpperLimit":"20.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"20.5",
                                        "OutcomeMeasurementLowerLimit":"20.5",
                                        "OutcomeMeasurementUpperLimit":"20.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 2: Booster Study",
                      "OutcomeMeasureDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Titer",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 2 of primary study",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"25"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"971.4",
                                        "OutcomeMeasurementLowerLimit":"750.5",
                                        "OutcomeMeasurementUpperLimit":"1257.4"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"749.0",
                                        "OutcomeMeasurementLowerLimit":"575.2",
                                        "OutcomeMeasurementUpperLimit":"975.3"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain Before Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Titer",
                      "OutcomeMeasureTimeFrame":"Before Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"263.5",
                                        "OutcomeMeasurementLowerLimit":"186.9",
                                        "OutcomeMeasurementUpperLimit":"371.3"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"224.2",
                                        "OutcomeMeasurementLowerLimit":"176.4",
                                        "OutcomeMeasurementUpperLimit":"285.1"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Week After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Titer",
                      "OutcomeMeasureTimeFrame":"1 Week after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"2159.3",
                                        "OutcomeMeasurementLowerLimit":"1568.4",
                                        "OutcomeMeasurementUpperLimit":"2972.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"1283.4",
                                        "OutcomeMeasurementLowerLimit":"939.4",
                                        "OutcomeMeasurementUpperLimit":"1753.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) of SARS-CoV-2 Reference-strain 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Titer",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"2035.5",
                                        "OutcomeMeasurementLowerLimit":"1502.2",
                                        "OutcomeMeasurementUpperLimit":"2758.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"943.3",
                                        "OutcomeMeasurementLowerLimit":"699.1",
                                        "OutcomeMeasurementUpperLimit":"1272.7"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain at Baseline: Booster Study",
                      "OutcomeMeasureDescription":"GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).",
                      "OutcomeMeasurePopulationDescription":"Data for this outcome was not analyzed as the immunogenicity samples were not tested for SARS-CoV-2 B.1.351-strain at Baseline as the South African strain was no longer of clinical interest and required responses have been well understood from other studies.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureTimeFrame":"Baseline (prior to Dose 1 of Primary study)",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"0"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"0"
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 2: Booster Study",
                      "OutcomeMeasureDescription":"GMTs and 2-sided 95% CIs were planned to be calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).",
                      "OutcomeMeasurePopulationDescription":"Data for this outcome was not analyzed as the immunogenicity samples were not tested for SARS-CoV-2 B.1.351-strain at 1 month after dose 2 as the South African strain was no longer of clinical interest and required responses have been well understood from other studies.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 2 of primary study",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"0"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"0"
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain Before Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Titer",
                      "OutcomeMeasureTimeFrame":"Before Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"103.0",
                                        "OutcomeMeasurementLowerLimit":"75.4",
                                        "OutcomeMeasurementUpperLimit":"140.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"94.0",
                                        "OutcomeMeasurementLowerLimit":"67.5",
                                        "OutcomeMeasurementUpperLimit":"130.8"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Week After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Titer",
                      "OutcomeMeasureTimeFrame":"1 Week after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"1614.1",
                                        "OutcomeMeasurementLowerLimit":"1172.8",
                                        "OutcomeMeasurementUpperLimit":"2221.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"1729.8",
                                        "OutcomeMeasurementLowerLimit":"1160.0",
                                        "OutcomeMeasurementUpperLimit":"2579.4"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Titers (GMTs) of SARS-CoV-2 B.1.351-strain 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Titer",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"1358.4",
                                        "OutcomeMeasurementLowerLimit":"968.5",
                                        "OutcomeMeasurementUpperLimit":"1905.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"1411.1",
                                        "OutcomeMeasurementLowerLimit":"950.1",
                                        "OutcomeMeasurementUpperLimit":"2095.9"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Booster Study",
                      "OutcomeMeasureDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Unit per milliliter",
                      "OutcomeMeasureTimeFrame":"Baseline (prior to Dose 1 of Primary study)",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"3.4",
                                        "OutcomeMeasurementLowerLimit":"2.0",
                                        "OutcomeMeasurementUpperLimit":"5.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"3.4",
                                        "OutcomeMeasurementLowerLimit":"2.3",
                                        "OutcomeMeasurementUpperLimit":"5.1"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 2: Booster Study",
                      "OutcomeMeasureDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Unit per milliliter",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 2 of primary study",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"6529.1",
                                        "OutcomeMeasurementLowerLimit":"5212.9",
                                        "OutcomeMeasurementUpperLimit":"8177.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"3796.9",
                                        "OutcomeMeasurementLowerLimit":"1899.8",
                                        "OutcomeMeasurementUpperLimit":"7588.4"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels Before Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Unit per milliliter",
                      "OutcomeMeasureTimeFrame":"Before Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"1834.5",
                                        "OutcomeMeasurementLowerLimit":"1458.5",
                                        "OutcomeMeasurementUpperLimit":"2307.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"1851.6",
                                        "OutcomeMeasurementLowerLimit":"1441.9",
                                        "OutcomeMeasurementUpperLimit":"2377.8"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Week After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Unit per milliliter",
                      "OutcomeMeasureTimeFrame":"1 Week after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"10756.9",
                                        "OutcomeMeasurementLowerLimit":"8478.9",
                                        "OutcomeMeasurementUpperLimit":"13647.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"10412.3",
                                        "OutcomeMeasurementLowerLimit":"7733.0",
                                        "OutcomeMeasurementUpperLimit":"14020.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Unit per milliliter",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"7983.0",
                                        "OutcomeMeasurementLowerLimit":"6266.0",
                                        "OutcomeMeasurementUpperLimit":"10170.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6676.9",
                                        "OutcomeMeasurementLowerLimit":"5242.6",
                                        "OutcomeMeasurementUpperLimit":"8503.6"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"From 1 Month after Dose 2 to 1 Week after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"1.6",
                                        "OutcomeMeasurementLowerLimit":"1.3",
                                        "OutcomeMeasurementUpperLimit":"2.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"2.7",
                                        "OutcomeMeasurementLowerLimit":"1.3",
                                        "OutcomeMeasurementUpperLimit":"5.9"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"From 1 Month after Dose 2 to 1 Month after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"1.2",
                                        "OutcomeMeasurementLowerLimit":"1.0",
                                        "OutcomeMeasurementUpperLimit":"1.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"1.8",
                                        "OutcomeMeasurementLowerLimit":"0.9",
                                        "OutcomeMeasurementUpperLimit":"3.6"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Week After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 week after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"Before Dose 3 to 1 Week after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"5.9",
                                        "OutcomeMeasurementLowerLimit":"4.9",
                                        "OutcomeMeasurementUpperLimit":"7.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"5.6",
                                        "OutcomeMeasurementLowerLimit":"4.4",
                                        "OutcomeMeasurementUpperLimit":"7.2"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels Before Dose 3 to 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 3 to the geometric mean concentration of IgG before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"Before Dose 3 to 1 Month after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"4.4",
                                        "OutcomeMeasurementLowerLimit":"3.7",
                                        "OutcomeMeasurementUpperLimit":"5.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"3.6",
                                        "OutcomeMeasurementLowerLimit":"2.9",
                                        "OutcomeMeasurementUpperLimit":"4.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"From 1 Month after Dose 2 to 1 Week after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"25"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"2.2",
                                        "OutcomeMeasurementLowerLimit":"1.6",
                                        "OutcomeMeasurementUpperLimit":"3.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"1.7",
                                        "OutcomeMeasurementLowerLimit":"1.3",
                                        "OutcomeMeasurementUpperLimit":"2.2"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after dose 2. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"From 1 Month after Dose 2 to 1 Month after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"25"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"2.1",
                                        "OutcomeMeasurementLowerLimit":"1.6",
                                        "OutcomeMeasurementUpperLimit":"2.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"1.2",
                                        "OutcomeMeasurementLowerLimit":"0.9",
                                        "OutcomeMeasurementUpperLimit":"1.6"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Week After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"Before Dose 3 to 1 Week after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"8.2",
                                        "OutcomeMeasurementLowerLimit":"5.3",
                                        "OutcomeMeasurementUpperLimit":"12.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"5.7",
                                        "OutcomeMeasurementLowerLimit":"4.5",
                                        "OutcomeMeasurementUpperLimit":"7.3"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 Reference-strain Before Dose 3 to 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 reference-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 reference-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"Before Dose 3 to 1 Month after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"7.7",
                                        "OutcomeMeasurementLowerLimit":"5.6",
                                        "OutcomeMeasurementUpperLimit":"10.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"4.2",
                                        "OutcomeMeasurementLowerLimit":"3.2",
                                        "OutcomeMeasurementUpperLimit":"5.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain From 1 Month After Dose 2 to 1 Week After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).",
                      "OutcomeMeasurePopulationDescription":"Data for this outcome was not analyzed as the immunogenicity samples from 1 month after dose 2 were not tested for SARS-CoV-2 B.1.351-strain as the South African strain was no longer of clinical interest and required responses have been well understood from other studies.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureTimeFrame":"From 1 Month after Dose 2 to 1 Week after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"0"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"0"
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain From 1 Month After Dose 2 to 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after dose 2. GMFRs were planned to be calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution).",
                      "OutcomeMeasurePopulationDescription":"Data for this outcome was not analyzed as the immunogenicity samples were not tested for SARS-CoV-2 B.1.351-strain at 1 month after dose 2 as the South African strain was no longer of clinical interest and required responses have been well understood from other studies.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureTimeFrame":"From 1 Month after Dose 2 to 1 Month after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"0"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"0"
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Week After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 week after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"Before Dose 3 to 1 Week after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"15.7",
                                        "OutcomeMeasurementLowerLimit":"11.2",
                                        "OutcomeMeasurementUpperLimit":"22.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"18.4",
                                        "OutcomeMeasurementLowerLimit":"13.8",
                                        "OutcomeMeasurementUpperLimit":"24.6"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rise (GMFRs) in SARS-CoV-2 B.1.351-strain Before Dose 3 to 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 B.1.351-strain at 1 month after Dose 3 to the geometric mean titers of SARS-CoV-2 B.1.351-strain before dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"Before Dose 3 to 1 Month after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"26"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"13.2",
                                        "OutcomeMeasurementLowerLimit":"9.6",
                                        "OutcomeMeasurementUpperLimit":"18.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"15.0",
                                        "OutcomeMeasurementLowerLimit":"11.3",
                                        "OutcomeMeasurementUpperLimit":"19.9"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Seroresponse to Reference Strain at 1 Month After Dose 2: Booster Study",
                      "OutcomeMeasureDescription":"Seroresponse was defined as greater than equal to (>=) 4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of >=4*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 2",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"25"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"100",
                                        "OutcomeMeasurementLowerLimit":"87.2",
                                        "OutcomeMeasurementUpperLimit":"100.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"100",
                                        "OutcomeMeasurementLowerLimit":"86.3",
                                        "OutcomeMeasurementUpperLimit":"100.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Seroresponse to Reference Strain Before Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of >=4*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"Before Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"25"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"92.6",
                                        "OutcomeMeasurementLowerLimit":"75.7",
                                        "OutcomeMeasurementUpperLimit":"99.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"92.0",
                                        "OutcomeMeasurementLowerLimit":"74.0",
                                        "OutcomeMeasurementUpperLimit":"99.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Seroresponse to Reference Strain 1 Week After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of >=4*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"1 Week after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"25"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"100.0",
                                        "OutcomeMeasurementLowerLimit":"87.2",
                                        "OutcomeMeasurementUpperLimit":"100.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"100.0",
                                        "OutcomeMeasurementLowerLimit":"86.3",
                                        "OutcomeMeasurementUpperLimit":"100.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Seroresponse to Reference Strain 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point. If the baseline measurement was below LLOQ, a post vaccination measurement of >=4*LLOQ was considered a seroresponse. Exact 2-sided 95% CI was based on the Clopper and Pearson method.",
                      "OutcomeMeasurePopulationDescription":"Booster evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, Dose 2 - primary study, Dose 3 - booster study within predefined window, had at least 1 valid immunogenicity result from blood sample collected within appropriate window at 1 month after Dose 3, were negative for both SARS-CoV-2 test at Dose 1,1-month post Dose 2, 3, and had no other protocol deviations determined by clinician. Here, \"N\" = participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Number",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Percentage of participants",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"27"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"25"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"100.0",
                                        "OutcomeMeasurementLowerLimit":"87.2",
                                        "OutcomeMeasurementUpperLimit":"100.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"100.0",
                                        "OutcomeMeasurementLowerLimit":"86.3",
                                        "OutcomeMeasurementUpperLimit":"100.0"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Seroresponse to B.1.351 Variant Strain at 1 Month After Dose 2: Booster Study",
                      "OutcomeMeasureDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.",
                      "OutcomeMeasurePopulationDescription":"Data for this outcome was not analyzed as the immunogenicity samples were not tested for SARS-CoV-2 B.1.351-strain at baseline and 1 month after dose 2 as the South African strain was no longer of clinical interest and required responses have been well understood from other studies.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 2",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"0"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"0"
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Seroresponse to B.1.351 Variant Strain Before Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.",
                      "OutcomeMeasurePopulationDescription":"Data for this outcome was not analyzed as the immunogenicity samples were not tested for SARS-CoV-2 B.1.351-strain at Baseline as the South African strain was no longer of clinical interest and required responses have been well understood from other studies.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureTimeFrame":"Before Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"0"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"0"
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Seroresponse to B.1.351 Variant Strain 1 Week After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.",
                      "OutcomeMeasurePopulationDescription":"Data for this outcome was not analyzed as the immunogenicity samples were not tested for SARS-CoV-2 B.1.351-strain at Baseline as the South African strain was no longer of clinical interest and required responses have been well understood from other studies.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureTimeFrame":"1 Week after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"0"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"0"
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Primary",
                      "OutcomeMeasureTitle":"Percentage of Participants With Seroresponse to B.1.351 Variant Strain 1 Month After Dose 3: Booster Study",
                      "OutcomeMeasureDescription":"Seroresponse was defined as >=4-fold increase from baseline (before Dose 1 in primary study) to the specified time point.",
                      "OutcomeMeasurePopulationDescription":"Data for this outcome was not analyzed as the immunogenicity samples were not tested for SARS-CoV-2 B.1.351-strain at Baseline as the South African strain was no longer of clinical interest and required responses have been well understood from other studies.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureTimeFrame":"1 Month after Dose 3",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                            "OutcomeGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"0"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"0"
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Secondary",
                      "OutcomeMeasureTitle":"Geometric Mean Concentrations (GMCs) of Full-Length S-Binding IgG Levels at Baseline and 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study",
                      "OutcomeMeasureDescription":"GMCs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5* LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, with Dose 2 received within predefined window, had at least 1 valid immunogenicity result from blood sample collected within an appropriate window at 1 month after Dose 2, were negative for both SARS-CoV-2 test during study and had no other protocol deviations determined by clinician. Here, N=participants evaluable for this outcome measure and n=participants evaluable at specified time points.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Unit per milliliter",
                      "OutcomeMeasureTimeFrame":"Baseline (before Dose 1), 1 Month after Dose 2",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 microgram (mcg) intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG002",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG003",
                            "OutcomeGroupTitle":"Pooled US Lots",
                            "OutcomeGroupDescription":"Participants randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1 + US Lot 2 + US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG004",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: EU Lot",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"324"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"311"
                                },{
                                  "OutcomeDenomCountGroupId":"OG002",
                                  "OutcomeDenomCountValue":"310"
                                },{
                                  "OutcomeDenomCountGroupId":"OG003",
                                  "OutcomeDenomCountValue":"945"
                                },{
                                  "OutcomeDenomCountGroupId":"OG004",
                                  "OutcomeDenomCountValue":"160"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"Baseline",
                            "OutcomeClassDenomList":{
                              "OutcomeClassDenom":[
                                {
                                  "OutcomeClassDenomUnits":"Participants",
                                  "OutcomeClassDenomCountList":{
                                    "OutcomeClassDenomCount":[
                                      {
                                        "OutcomeClassDenomCountGroupId":"OG000",
                                        "OutcomeClassDenomCountValue":"323"
                                      },{
                                        "OutcomeClassDenomCountGroupId":"OG001",
                                        "OutcomeClassDenomCountValue":"311"
                                      },{
                                        "OutcomeClassDenomCountGroupId":"OG002",
                                        "OutcomeClassDenomCountValue":"310"
                                      },{
                                        "OutcomeClassDenomCountGroupId":"OG003",
                                        "OutcomeClassDenomCountValue":"944"
                                      },{
                                        "OutcomeClassDenomCountGroupId":"OG004",
                                        "OutcomeClassDenomCountValue":"160"
                                      }
                                    ]
                                  }
                                }
                              ]
                            },
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"3.1",
                                        "OutcomeMeasurementLowerLimit":"2.7",
                                        "OutcomeMeasurementUpperLimit":"3.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"2.6",
                                        "OutcomeMeasurementLowerLimit":"2.3",
                                        "OutcomeMeasurementUpperLimit":"3.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"2.6",
                                        "OutcomeMeasurementLowerLimit":"2.2",
                                        "OutcomeMeasurementUpperLimit":"3.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"2.8",
                                        "OutcomeMeasurementLowerLimit":"2.5",
                                        "OutcomeMeasurementUpperLimit":"3.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"2.6",
                                        "OutcomeMeasurementLowerLimit":"2.1",
                                        "OutcomeMeasurementUpperLimit":"3.2"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"1 Month After Dose 2",
                            "OutcomeClassDenomList":{
                              "OutcomeClassDenom":[
                                {
                                  "OutcomeClassDenomUnits":"Participants",
                                  "OutcomeClassDenomCountList":{
                                    "OutcomeClassDenomCount":[
                                      {
                                        "OutcomeClassDenomCountGroupId":"OG000",
                                        "OutcomeClassDenomCountValue":"324"
                                      },{
                                        "OutcomeClassDenomCountGroupId":"OG001",
                                        "OutcomeClassDenomCountValue":"311"
                                      },{
                                        "OutcomeClassDenomCountGroupId":"OG002",
                                        "OutcomeClassDenomCountValue":"310"
                                      },{
                                        "OutcomeClassDenomCountGroupId":"OG003",
                                        "OutcomeClassDenomCountValue":"945"
                                      },{
                                        "OutcomeClassDenomCountGroupId":"OG004",
                                        "OutcomeClassDenomCountValue":"160"
                                      }
                                    ]
                                  }
                                }
                              ]
                            },
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"6269.8",
                                        "OutcomeMeasurementLowerLimit":"5717.7",
                                        "OutcomeMeasurementUpperLimit":"6875.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"6222.3",
                                        "OutcomeMeasurementLowerLimit":"5721.5",
                                        "OutcomeMeasurementUpperLimit":"6766.9"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"6818.9",
                                        "OutcomeMeasurementLowerLimit":"6280.9",
                                        "OutcomeMeasurementUpperLimit":"7403.1"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"6428.7",
                                        "OutcomeMeasurementLowerLimit":"6116.6",
                                        "OutcomeMeasurementUpperLimit":"6756.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"6098.9",
                                        "OutcomeMeasurementLowerLimit":"5446.0",
                                        "OutcomeMeasurementUpperLimit":"6830.1"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Secondary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rises (GMFRs) in Full-Length S-Binding lgG Levels From Baseline to 1 Month After Dose 2 for 30 mcg Dose of BNT162b2: Primary Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5*LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, with Dose 2 received within predefined window, had at least 1 valid immunogenicity result from blood sample collected within an appropriate window at 1 month after Dose 2, were negative for both SARS-CoV-2 test (RT-PCR and N-blinding antibody) during study and had no other protocol deviations determined by clinician. Here, \"N\"= participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"From Baseline (before Dose 1) up to 1 Month after Dose 2",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 microgram (mcg) intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG002",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG003",
                            "OutcomeGroupTitle":"Pooled US Lots",
                            "OutcomeGroupDescription":"Participants randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1 + US Lot 2 + US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG004",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: EU Lot",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"323"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"311"
                                },{
                                  "OutcomeDenomCountGroupId":"OG002",
                                  "OutcomeDenomCountValue":"310"
                                },{
                                  "OutcomeDenomCountGroupId":"OG003",
                                  "OutcomeDenomCountValue":"944"
                                },{
                                  "OutcomeDenomCountGroupId":"OG004",
                                  "OutcomeDenomCountValue":"160"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"2036.6",
                                        "OutcomeMeasurementLowerLimit":"1744.5",
                                        "OutcomeMeasurementUpperLimit":"2377.7"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"2367.1",
                                        "OutcomeMeasurementLowerLimit":"2028.6",
                                        "OutcomeMeasurementUpperLimit":"2762.2"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG002",
                                        "OutcomeMeasurementValue":"2645.2",
                                        "OutcomeMeasurementLowerLimit":"2271.2",
                                        "OutcomeMeasurementUpperLimit":"3080.8"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG003",
                                        "OutcomeMeasurementValue":"2331.9",
                                        "OutcomeMeasurementLowerLimit":"2133.7",
                                        "OutcomeMeasurementUpperLimit":"2548.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG004",
                                        "OutcomeMeasurementValue":"2373.8",
                                        "OutcomeMeasurementLowerLimit":"1901.2",
                                        "OutcomeMeasurementUpperLimit":"2963.9"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Secondary",
                      "OutcomeMeasureTitle":"Geometric Mean Titers (GMT) of SARS-CoV-2 Neutralizing Titers at Baseline and 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study",
                      "OutcomeMeasureDescription":"GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5* LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, with Dose 2 received within predefined window, had at least 1 valid immunogenicity result from blood sample collected within an appropriate window at 1 month after Dose 2, were negative for both SARS-CoV-2 test (RT-PCR and N-blinding antibody) during study and had no other protocol deviations determined by clinician. Here, \"N\"= participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Titer",
                      "OutcomeMeasureTimeFrame":"Baseline (before Dose 1), 1 Month after Dose 2",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 microgram (mcg) intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"324"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"318"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeClassTitle":"Baseline",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"20.5",
                                        "OutcomeMeasurementLowerLimit":"20.5",
                                        "OutcomeMeasurementUpperLimit":"20.5"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"20.5",
                                        "OutcomeMeasurementLowerLimit":"20.5",
                                        "OutcomeMeasurementUpperLimit":"20.5"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          },{
                            "OutcomeClassTitle":"1 Month after Dose 2",
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"969.6",
                                        "OutcomeMeasurementLowerLimit":"905.7",
                                        "OutcomeMeasurementUpperLimit":"1038.0"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"913.0",
                                        "OutcomeMeasurementLowerLimit":"843.4",
                                        "OutcomeMeasurementUpperLimit":"988.3"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    },{
                      "OutcomeMeasureType":"Secondary",
                      "OutcomeMeasureTitle":"Geometric Mean Fold Rises (GMFRs) in SARS-CoV-2 Neutralizing Titers From Baseline to 1 Month After Dose 2 for 20 mcg and 30 mcg Dose of BNT162b2 From US Lot 1: Primary Study",
                      "OutcomeMeasureDescription":"GMFRs were defined as ratios of the geometric mean titers of SARS-CoV-2 at 1 month after Dose 2 to the geometric mean titers of SARS-CoV-2 at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5* LLOQ.",
                      "OutcomeMeasurePopulationDescription":"Evaluable immunogenicity population: Participants who received 2 doses of vaccine in primary study, with Dose 2 received within predefined window, had at least 1 valid immunogenicity result from blood sample collected within an appropriate window at 1 month after Dose 2, were negative for both SARS-CoV-2 test (RT-PCR and N-blinding antibody) during study and had no other protocol deviations determined by clinician. Here, \"N\"= participants evaluable for this outcome measure.",
                      "OutcomeMeasureReportingStatus":"Posted",
                      "OutcomeMeasureParamType":"Geometric Mean",
                      "OutcomeMeasureDispersionType":"95% Confidence Interval",
                      "OutcomeMeasureUnitOfMeasure":"Fold rise",
                      "OutcomeMeasureTimeFrame":"From Baseline (before Dose 1) up to 1 Month after Dose 2",
                      "OutcomeGroupList":{
                        "OutcomeGroup":[
                          {
                            "OutcomeGroupId":"OG000",
                            "OutcomeGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          },{
                            "OutcomeGroupId":"OG001",
                            "OutcomeGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                            "OutcomeGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months."
                          }
                        ]
                      },
                      "OutcomeDenomList":{
                        "OutcomeDenom":[
                          {
                            "OutcomeDenomUnits":"Participants",
                            "OutcomeDenomCountList":{
                              "OutcomeDenomCount":[
                                {
                                  "OutcomeDenomCountGroupId":"OG000",
                                  "OutcomeDenomCountValue":"324"
                                },{
                                  "OutcomeDenomCountGroupId":"OG001",
                                  "OutcomeDenomCountValue":"318"
                                }
                              ]
                            }
                          }
                        ]
                      },
                      "OutcomeClassList":{
                        "OutcomeClass":[
                          {
                            "OutcomeCategoryList":{
                              "OutcomeCategory":[
                                {
                                  "OutcomeMeasurementList":{
                                    "OutcomeMeasurement":[
                                      {
                                        "OutcomeMeasurementGroupId":"OG000",
                                        "OutcomeMeasurementValue":"47.3",
                                        "OutcomeMeasurementLowerLimit":"44.2",
                                        "OutcomeMeasurementUpperLimit":"50.6"
                                      },{
                                        "OutcomeMeasurementGroupId":"OG001",
                                        "OutcomeMeasurementValue":"44.5",
                                        "OutcomeMeasurementLowerLimit":"41.1",
                                        "OutcomeMeasurementUpperLimit":"48.2"
                                      }
                                    ]
                                  }
                                }
                              ]
                            }
                          }
                        ]
                      }
                    }
                  ]
                }
              },
              "AdverseEventsModule":{
                "EventsFrequencyThreshold":"1",
                "EventsTimeFrame":"AEs and SAEs-For primary study: From Dose 1 to 1 Month after Dose 2 (up to a maximum of 2 months); For booster study: From Dose 3 to 1 Month after Dose 3 (up to a maximum of 35 days); Local reactions/systemic events: Within 7 days after each dose",
                "EventsDescription":"Safety population: participants who received at least 1 dose and had safety data available. AEs included events collected in electronic diary (local and systemic reactions; systematic assessment) and events collected on case report form at each visit (non-systematic assessment). 1 participant randomized to US Lot 1 was administered US Lot 1 for Dose 1 and US Lot 3 for Dose 2, therefore, the participant was included in both reporting groups (US Lot 1 and US Lot 3) for non-SAEs.",
                "EventGroupList":{
                  "EventGroup":[
                    {
                      "EventGroupId":"EG000",
                      "EventGroupTitle":"BNT162b2 30 mcg: US Lot 1",
                      "EventGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 1) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months.",
                      "EventGroupDeathsNumAffected":"0",
                      "EventGroupDeathsNumAtRisk":"351",
                      "EventGroupSeriousNumAffected":"0",
                      "EventGroupSeriousNumAtRisk":"351",
                      "EventGroupOtherNumAffected":"341",
                      "EventGroupOtherNumAtRisk":"351"
                    },{
                      "EventGroupId":"EG001",
                      "EventGroupTitle":"BNT162b2 30 mcg: US Lot 2",
                      "EventGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 2) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months.",
                      "EventGroupDeathsNumAffected":"0",
                      "EventGroupDeathsNumAtRisk":"352",
                      "EventGroupSeriousNumAffected":"0",
                      "EventGroupSeriousNumAtRisk":"352",
                      "EventGroupOtherNumAffected":"336",
                      "EventGroupOtherNumAtRisk":"352"
                    },{
                      "EventGroupId":"EG002",
                      "EventGroupTitle":"BNT162b2 30 mcg: US Lot 3",
                      "EventGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (US Lot 3) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months.",
                      "EventGroupDeathsNumAffected":"0",
                      "EventGroupDeathsNumAtRisk":"346",
                      "EventGroupSeriousNumAffected":"1",
                      "EventGroupSeriousNumAtRisk":"346",
                      "EventGroupOtherNumAffected":"335",
                      "EventGroupOtherNumAtRisk":"347"
                    },{
                      "EventGroupId":"EG003",
                      "EventGroupTitle":"BNT162b2 30 mcg: EU Lot",
                      "EventGroupDescription":"Participants were randomized in primary study to receive 30 mcg intramuscular dose of BNT162b2 (EU Lot) vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months.",
                      "EventGroupDeathsNumAffected":"0",
                      "EventGroupDeathsNumAtRisk":"173",
                      "EventGroupSeriousNumAffected":"1",
                      "EventGroupSeriousNumAtRisk":"173",
                      "EventGroupOtherNumAffected":"165",
                      "EventGroupOtherNumAtRisk":"173"
                    },{
                      "EventGroupId":"EG004",
                      "EventGroupTitle":"BNT162b2 20 mcg: US Lot 1",
                      "EventGroupDescription":"Participants were randomized in primary study to receive 20 mcg intramuscular dose of BNT162b2 vaccine as 2-dose schedule separated by 21 days. Participants were followed up for safety for up to 28-35 days after second dose of vaccine, for a maximum of 2 months.",
                      "EventGroupDeathsNumAffected":"0",
                      "EventGroupDeathsNumAtRisk":"351",
                      "EventGroupSeriousNumAffected":"0",
                      "EventGroupSeriousNumAtRisk":"351",
                      "EventGroupOtherNumAffected":"342",
                      "EventGroupOtherNumAtRisk":"351"
                    },{
                      "EventGroupId":"EG005",
                      "EventGroupTitle":"BNT162b2 30 mcg: Booster Dose",
                      "EventGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination.",
                      "EventGroupDeathsNumAffected":"0",
                      "EventGroupDeathsNumAtRisk":"31",
                      "EventGroupSeriousNumAffected":"0",
                      "EventGroupSeriousNumAtRisk":"31",
                      "EventGroupOtherNumAffected":"30",
                      "EventGroupOtherNumAtRisk":"31"
                    },{
                      "EventGroupId":"EG006",
                      "EventGroupTitle":"BNT162b2.B.1.351 30 mcg: Booster Dose",
                      "EventGroupDescription":"Participants who received 2 doses of 30 mcg BNT162b2 vaccine in primary study from US Lot 1, 2 or 3 were randomized to booster study to receive a single 30 mcg intramuscular dose of BNT162b2.B.1.351 vaccine at 3 months after second dose in the primary study. Participants were followed up for safety for up to 28-35 days after vaccination.",
                      "EventGroupDeathsNumAffected":"0",
                      "EventGroupDeathsNumAtRisk":"31",
                      "EventGroupSeriousNumAffected":"0",
                      "EventGroupSeriousNumAtRisk":"31",
                      "EventGroupOtherNumAffected":"31",
                      "EventGroupOtherNumAtRisk":"31"
                    }
                  ]
                },
                "SeriousEventList":{
                  "SeriousEvent":[
                    {
                      "SeriousEventTerm":"Migrainosus",
                      "SeriousEventOrganSystem":"Nervous system disorders",
                      "SeriousEventSourceVocabulary":"MedDRA 24.0",
                      "SeriousEventAssessmentType":"Non-systematic Assessment",
                      "SeriousEventStatsList":{
                        "SeriousEventStats":[
                          {
                            "SeriousEventStatsGroupId":"EG000",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"351"
                          },{
                            "SeriousEventStatsGroupId":"EG001",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"352"
                          },{
                            "SeriousEventStatsGroupId":"EG002",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"346"
                          },{
                            "SeriousEventStatsGroupId":"EG003",
                            "SeriousEventStatsNumAffected":"1",
                            "SeriousEventStatsNumAtRisk":"173"
                          },{
                            "SeriousEventStatsGroupId":"EG004",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"351"
                          },{
                            "SeriousEventStatsGroupId":"EG005",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"31"
                          },{
                            "SeriousEventStatsGroupId":"EG006",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "SeriousEventTerm":"Abortion spontaneous",
                      "SeriousEventOrganSystem":"Pregnancy, puerperium and perinatal conditions",
                      "SeriousEventSourceVocabulary":"MedDRA 24.0",
                      "SeriousEventAssessmentType":"Non-systematic Assessment",
                      "SeriousEventStatsList":{
                        "SeriousEventStats":[
                          {
                            "SeriousEventStatsGroupId":"EG000",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"351"
                          },{
                            "SeriousEventStatsGroupId":"EG001",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"352"
                          },{
                            "SeriousEventStatsGroupId":"EG002",
                            "SeriousEventStatsNumAffected":"1",
                            "SeriousEventStatsNumAtRisk":"346"
                          },{
                            "SeriousEventStatsGroupId":"EG003",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"173"
                          },{
                            "SeriousEventStatsGroupId":"EG004",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"351"
                          },{
                            "SeriousEventStatsGroupId":"EG005",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"31"
                          },{
                            "SeriousEventStatsGroupId":"EG006",
                            "SeriousEventStatsNumAffected":"0",
                            "SeriousEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    }
                  ]
                },
                "OtherEventList":{
                  "OtherEvent":[
                    {
                      "OtherEventTerm":"Diarrhoea",
                      "OtherEventOrganSystem":"Gastrointestinal disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"57",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"50",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"48",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"26",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"54",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"5",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"2",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Vomiting",
                      "OtherEventOrganSystem":"Gastrointestinal disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"10",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"7",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"12",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"4",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"8",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"1",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Chills",
                      "OtherEventOrganSystem":"General disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"115",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"120",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"129",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"56",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"92",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"8",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"6",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Fatigue",
                      "OtherEventOrganSystem":"General disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"276",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"259",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"281",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"133",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"265",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"21",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"26",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Injection site erythema",
                      "OtherEventOrganSystem":"General disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"16",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"19",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"23",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"8",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"16",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"3",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"1",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Injection site pain",
                      "OtherEventOrganSystem":"General disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"319",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"302",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"316",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"158",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"314",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"28",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"29",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Injection site swelling",
                      "OtherEventOrganSystem":"General disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"21",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"31",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"25",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"8",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"22",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"2",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"2",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Pyrexia",
                      "OtherEventOrganSystem":"General disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"26",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"22",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"29",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"16",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"20",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"1",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"2",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Arthralgia",
                      "OtherEventOrganSystem":"Musculoskeletal and connective tissue disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"82",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"96",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"83",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"42",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"78",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"4",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"4",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Myalgia",
                      "OtherEventOrganSystem":"Musculoskeletal and connective tissue disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"136",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"153",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"150",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"76",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"142",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"13",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"6",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Headache",
                      "OtherEventOrganSystem":"Nervous system disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"234",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"229",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"223",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"119",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"224",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"13",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"18",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Syncope",
                      "OtherEventOrganSystem":"Nervous system disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Non-systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"2",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Benign abdominal neoplasm",
                      "OtherEventOrganSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Non-systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"1",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Lymphadenopathy",
                      "OtherEventOrganSystem":"Blood and lymphatic system disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Non-systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"1",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Rash",
                      "OtherEventOrganSystem":"Skin and subcutaneous tissue disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Non-systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"1",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"1",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"3",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"2",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    },{
                      "OtherEventTerm":"Neck pain",
                      "OtherEventOrganSystem":"Musculoskeletal and connective tissue disorders",
                      "OtherEventSourceVocabulary":"MedDRA 24.0",
                      "OtherEventAssessmentType":"Non-systematic Assessment",
                      "OtherEventStatsList":{
                        "OtherEventStats":[
                          {
                            "OtherEventStatsGroupId":"EG000",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG001",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"352"
                          },{
                            "OtherEventStatsGroupId":"EG002",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"347"
                          },{
                            "OtherEventStatsGroupId":"EG003",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"173"
                          },{
                            "OtherEventStatsGroupId":"EG004",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"351"
                          },{
                            "OtherEventStatsGroupId":"EG005",
                            "OtherEventStatsNumAffected":"0",
                            "OtherEventStatsNumAtRisk":"31"
                          },{
                            "OtherEventStatsGroupId":"EG006",
                            "OtherEventStatsNumAffected":"1",
                            "OtherEventStatsNumAtRisk":"31"
                          }
                        ]
                      }
                    }
                  ]
                }
              },
              "MoreInfoModule":{
                "CertainAgreement":{
                  "AgreementPISponsorEmployee":"No",
                  "AgreementRestrictionType":"OTHER",
                  "AgreementRestrictiveAgreement":"Yes",
                  "AgreementOtherDetails":"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."
                },
                "PointOfContact":{
                  "PointOfContactTitle":"BioNTech clinical trials patient information",
                  "PointOfContactOrganization":"BioNTech SE",
                  "PointOfContactEMail":"patients@biontech.de",
                  "PointOfContactPhone":"+49 6131 9084",
                  "PointOfContactPhoneExt":"0"
                }
              }
            },
            "DocumentSection":{
              "LargeDocumentModule":{
                "LargeDocList":{
                  "LargeDoc":[
                    {
                      "LargeDocTypeAbbrev":"Prot",
                      "LargeDocHasProtocol":"Yes",
                      "LargeDocHasSAP":"No",
                      "LargeDocHasICF":"No",
                      "LargeDocLabel":"Study Protocol",
                      "LargeDocDate":"May 3, 2021",
                      "LargeDocUploadDate":"07/11/2022 17:20",
                      "LargeDocFilename":"Prot_000.pdf"
                    },{
                      "LargeDocTypeAbbrev":"SAP",
                      "LargeDocHasProtocol":"No",
                      "LargeDocHasSAP":"Yes",
                      "LargeDocHasICF":"No",
                      "LargeDocLabel":"Statistical Analysis Plan",
                      "LargeDocDate":"October 15, 2021",
                      "LargeDocUploadDate":"07/11/2022 17:20",
                      "LargeDocFilename":"SAP_001.pdf"
                    }
                  ]
                }
              }
            },
            "DerivedSection":{
              "MiscInfoModule":{
                "VersionHolder":"August 17, 2023",
                "SubmissionTracking":{}
              },
              "ConditionBrowseModule":{
                "ConditionMeshList":{
                  "ConditionMesh":[
                    {
                      "ConditionMeshId":"D000086382",
                      "ConditionMeshTerm":"COVID-19"
                    }
                  ]
                },
                "ConditionAncestorList":{
                  "ConditionAncestor":[
                    {
                      "ConditionAncestorId":"D000011024",
                      "ConditionAncestorTerm":"Pneumonia, Viral"
                    },{
                      "ConditionAncestorId":"D000011014",
                      "ConditionAncestorTerm":"Pneumonia"
                    },{
                      "ConditionAncestorId":"D000012141",
                      "ConditionAncestorTerm":"Respiratory Tract Infections"
                    },{
                      "ConditionAncestorId":"D000007239",
                      "ConditionAncestorTerm":"Infections"
                    },{
                      "ConditionAncestorId":"D000014777",
                      "ConditionAncestorTerm":"Virus Diseases"
                    },{
                      "ConditionAncestorId":"D000018352",
                      "ConditionAncestorTerm":"Coronavirus Infections"
                    },{
                      "ConditionAncestorId":"D000003333",
                      "ConditionAncestorTerm":"Coronaviridae Infections"
                    },{
                      "ConditionAncestorId":"D000030341",
                      "ConditionAncestorTerm":"Nidovirales Infections"
                    },{
                      "ConditionAncestorId":"D000012327",
                      "ConditionAncestorTerm":"RNA Virus Infections"
                    },{
                      "ConditionAncestorId":"D000008171",
                      "ConditionAncestorTerm":"Lung Diseases"
                    },{
                      "ConditionAncestorId":"D000012140",
                      "ConditionAncestorTerm":"Respiratory Tract Diseases"
                    }
                  ]
                },
                "ConditionBrowseLeafList":{
                  "ConditionBrowseLeaf":[
                    {
                      "ConditionBrowseLeafId":"M2562",
                      "ConditionBrowseLeafName":"COVID-19",
                      "ConditionBrowseLeafAsFound":"COVID-19",
                      "ConditionBrowseLeafRelevance":"high"
                    },{
                      "ConditionBrowseLeafId":"M9973",
                      "ConditionBrowseLeafName":"Infections",
                      "ConditionBrowseLeafRelevance":"low"
                    },{
                      "ConditionBrowseLeafId":"M6058",
                      "ConditionBrowseLeafName":"Communicable Diseases",
                      "ConditionBrowseLeafRelevance":"low"
                    },{
                      "ConditionBrowseLeafId":"M20180",
                      "ConditionBrowseLeafName":"Coronavirus Infections",
                      "ConditionBrowseLeafRelevance":"low"
                    },{
                      "ConditionBrowseLeafId":"M13594",
                      "ConditionBrowseLeafName":"Pneumonia",
                      "ConditionBrowseLeafRelevance":"low"
                    },{
                      "ConditionBrowseLeafId":"M13604",
                      "ConditionBrowseLeafName":"Pneumonia, Viral",
                      "ConditionBrowseLeafRelevance":"low"
                    },{
                      "ConditionBrowseLeafId":"M14668",
                      "ConditionBrowseLeafName":"Respiratory Tract Infections",
                      "ConditionBrowseLeafRelevance":"low"
                    },{
                      "ConditionBrowseLeafId":"M17212",
                      "ConditionBrowseLeafName":"Virus Diseases",
                      "ConditionBrowseLeafRelevance":"low"
                    },{
                      "ConditionBrowseLeafId":"M6245",
                      "ConditionBrowseLeafName":"Coronaviridae Infections",
                      "ConditionBrowseLeafRelevance":"low"
                    },{
                      "ConditionBrowseLeafId":"M23375",
                      "ConditionBrowseLeafName":"Nidovirales Infections",
                      "ConditionBrowseLeafRelevance":"low"
                    },{
                      "ConditionBrowseLeafId":"M14839",
                      "ConditionBrowseLeafName":"RNA Virus Infections",
                      "ConditionBrowseLeafRelevance":"low"
                    },{
                      "ConditionBrowseLeafId":"M10858",
                      "ConditionBrowseLeafName":"Lung Diseases",
                      "ConditionBrowseLeafRelevance":"low"
                    },{
                      "ConditionBrowseLeafId":"M14667",
                      "ConditionBrowseLeafName":"Respiratory Tract Diseases",
                      "ConditionBrowseLeafRelevance":"low"
                    }
                  ]
                },
                "ConditionBrowseBranchList":{
                  "ConditionBrowseBranch":[
                    {
                      "ConditionBrowseBranchAbbrev":"BC01",
                      "ConditionBrowseBranchName":"Infections"
                    },{
                      "ConditionBrowseBranchAbbrev":"BC08",
                      "ConditionBrowseBranchName":"Respiratory Tract (Lung and Bronchial) Diseases"
                    },{
                      "ConditionBrowseBranchAbbrev":"All",
                      "ConditionBrowseBranchName":"All Conditions"
                    },{
                      "ConditionBrowseBranchAbbrev":"BC23",
                      "ConditionBrowseBranchName":"Symptoms and General Pathology"
                    }
                  ]
                }
              },
              "InterventionBrowseModule":{
                "InterventionBrowseLeafList":{
                  "InterventionBrowseLeaf":[
                    {
                      "InterventionBrowseLeafId":"M17050",
                      "InterventionBrowseLeafName":"Vaccines",
                      "InterventionBrowseLeafRelevance":"low"
                    }
                  ]
                },
                "InterventionBrowseBranchList":{
                  "InterventionBrowseBranch":[
                    {
                      "InterventionBrowseBranchAbbrev":"All",
                      "InterventionBrowseBranchName":"All Drugs and Chemicals"
                    }
                  ]
                }
              }
            }
          }
        }
      ]
    }
  }
  